Schizophrenia is a complex and multifactorial disorder generally diagnosed in young adults at the time of the first psychotic episode of delusions and hallucinations. These positive symptoms can be controlled in most patients by currently-available antipsychotics. Conversely, they are poorly effective against concomitant neurocognitive dysfunction, deficits in social cognition and negative symptoms (NS), which strongly contribute to poor functional outcome. The precise notion of NS has evolved over the past century, with recent studies -underpinned by novel rating methods -suggesting two major sub-domains: "decreased emotional expression", incorporating blunted affect and poverty of speech, and "avolition", which embraces amotivation, asociality and "anhedonia" (inability to anticipate pleasure). Recent studies implicate a dysfunction of frontocortico-temporal networks in the aetiology of NS, together with a European Neuropsychopharmacology (2014) 24, 645-692 disruption of cortico-striatal circuits, though other structures are also involved, like the insular and parietal cortices, amygdala and thalamus. At the cellular level, a disruption of GABAergicglutamatergic balance, dopaminergic signalling and, possibly, oxytocinergic and cannibinoidergic transmission may be involved. Several agents are currently under clinical investigation for the potentially improved control of NS, including oxytocin itself, N-Methyl-D-Aspartate receptor modulators and minocycline. Further, magnetic-electrical "stimulation" strategies to recruit cortical circuits and "cognitive-behavioural-psychosocial" therapies likewise hold promise. To acquire novel insights into the causes and treatment of NS, experimental study is crucial, and opportunities are emerging for improved genetic, pharmacological and developmental modelling, together with more refined readouts related to deficits in reward, sociality and "expression". The present article comprises an integrative overview of the above issues as a platform for this Special Issue of European Neuropsychopharmacology in which five clinical and five preclinical articles treat individual themes in greater detail. This Volume provides, then, a framework for progress in the understanding -and ultimately control -of the debilitating NS of schizophrenia. & 2014 Elsevier B.V. and ECNP. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction 1.1. Schizophrenia: core characteristics and inadequate current management Schizophrenia is a chronic, life-long and debilitating disorder which is triggered in a complex, heterogeneous and multifactorial fashion by a diverse palette of genetic, epigenetic, developmental and environmental risk factors (Figure 1 ) (Millan, 2013; Sullivan et al., 2012; Rapoport et al., 2012) . It occurs with an incidence of at least 0.7% of the population and, quite apart from personal distress, schizophrenia has a huge socioeconomic burden, mostly in terms of indirect costs like loss of employment and social support (Wittchen et al., 2011) . Diagnosis generally occurs in the young adult (or in late adolescence) with the advent of the first frank psychotic episode, often in the wake of a high-risk, prodromal period in which occasional and/or attenuated psychotic symptoms may occur -though such high risk individuals may eventually transit to another psychiatric disorder like depression (Fusar-Poli et al., 2013a Sabbag et al., 2011) .
Psychosis corresponds to the most familiar cluster of cardinal symptoms, termed positive, and including delusions and hallucinations (Buchanan et al., 2010; Huxley and Fonseca, 2014; Leucht et al., 2013; Tandon et al., 2013) . Positive symptoms have long been treated by "first-generation" neuroleptics like haloperidol and chlorpromazine; by clozapine; and by a range of more recently-developed "second-generation" antipsychotics including risperidone, olanzapine and aripiprazole (AsenjoLobos et al., 2010; Citrome, 2013; Hartling et al., 2012; Leucht et al., 2009 Leucht et al., , 2013 Naber and Lambert, 2009) . Nonetheless, control is often incomplete and some 20-30% of patients are considered refractory (not responsive to at least two different treatments). Despite decades of effort to find successor agents of improved efficacy, clozapine remains the most effective agent in otherwise non-responsive patients. However, as outlined below, clozapine shares the comparative inactivity of other classes of antipsychotic for the management of neurocognitive dysfunction, impaired social cognition and negative symptoms (NS) (Asenjo-Lobos et al., 2010; Leucht et al., 2009 Leucht et al., , 2013 .
Deficits in multiple domains of "neurocognition" are marked, ranging from attention to working memory to executive function, and they are little improved by medication, though Cognitive Remediation Therapy (Section 4.7) is attracting interest as an alternative therapeutic approach (Buchanan et al., 2010; Carter and Barch, 2007; Kalkstein et al., 2010; Leucht et al., 2009 Leucht et al., , 2013 Millan et al., 2012; Naber and Lambert, 2009; Wykes et al., 2011) . The poor response to antipsychotics is hardly surprising since blockade of dopamine D2 receptors, muscarinic M1 receptors, histamine H1 receptors and α1-adrenoceptors will compromise mnemonic performance and overwhelm any potentially beneficial influence on cognition, such as that afforded by antagonism of frontocortical D3 receptors or α2-adrenoceptors (Brosda et al., 2014; Citrome, 2013; Millan et al., 2000 Millan et al., , 2012 Nakajima et al., 2013) . This may at least partially explain why numerous mechanisms evaluated as "add-on" therapies to antipsychotics have disappointed for improving neurocognition (Buchanan et al., 2011a (Buchanan et al., , 2011b Millan et al., 2012) .
A further domain of poorly-treated impairment in schizophrenia is social cognition which refers to mechanisms for understanding and interpreting the mental states, gestures, behaviours and facial expressions of others, and which also embraces the understanding of verbal and non-verbal modes of communication (Section 2.3) (Adolphs, 2009; Bora et al., 2009; Brown et al., 2012; Brüne, 2005; Fitch et al., 2010; Frith and Frith, 2012; Kalkstein et al., 2010; Millan and Bales, 2013; Rushworth et al., 2013) . By analogy to "neurocognitive impairment", deficits in social cognition are essentially refractory to existing antipsychotics yet, with the exception of some preliminary trials with oxytocin (Section 4.8), there have been comparatively few efforts to specifically redress the compromised social cognition of schizophrenia Meyer-Lindenberg et al., 2011; Millan et al., 2012) . This is unfortunate since impaired social cognition has grave repercussions for functional outcome and may drive other symptoms, including NS (Section 2.2) (Brüne, 2005; Foussias et al., 2014; Green et al., 2008 Green et al., , 2012 Hoe et al., 2012; Millan et al., 2012) .
The NS of schizophrenia, which encompass blunted affect, poverty of speech (alogia), amotivation, anticipatory anhedonia and asociality, are likewise poorly-treated and severely interfere with the functional status of patients (Table 1) (Blanchard and Cohen, 2006; Boonstra et al., 2012; Kaiser et al., 2010; Kirkpatrick et al., 2006; Kring and Elis, 2014; Konstantakopoulos et al., 2011; Messinger et al., 2011) . They comprise the subject of this Special Issue of European Neuropsychopharmacology which is, to the best of our knowledge, the first of its kind -at least in recent years -and embraces both clinical and preclinical facets of NS.
Organisation of the Special Volume, and aims of this introductory article
Research and drug development in schizophrenia is at something of a watershed with the recognition that secondgeneration antipsychotics do not offer any major advantages in terms of efficacy and breadth of therapeutic activity over previously-available agents -and certainly not over clozapine for refractory patients (Section 1.1).
This would seem, then, an opportune moment to devote a Special Volume to incapacitating NS. As reflected in the 800 or so Hits generated by PubMed for "schizophrenia and NS" in 2013, there has been a recent resurgence of interest reflecting: improved insights into the interrelationship of NS with other symptoms of schizophrenia; characterisation of two inter-related but distinguishable sub-domains of dysfunction, "decreased emotional expression" and "avolition"; the introduction of improved methods of clinical evaluation; the imminent impact of Diagnostic and Statistical Manual (DSM)-5; increasing awareness of "NS-like" changes in other psychiatric and neurological disorders; attempts to better couple NS to underlying neural pathophysiology -if necessary transgressing nosological boundaries; ongoing pivotal trials of potentially novel medication; and efforts to refine and diversify the experimental study of NS. Further, in the spate of disappointing results of mainly add-on studies of new drugs for restoring neurocognition in schizophrenia , there is an emerging feeling that comparable efforts might better be invested in novel pharmacotherapeutic and "alternative" strategies for countering poorly treated NS -and interrelated deficits in social cognition -in view of their mutually detrimental impact on the real-world function of patients (Section 2.3).
It would be difficult to cover every single facet of NS in a single tome, yet the majority of core issues are discussed in this Special Volume which, in addition to this introductory synthesis, contains a balanced selection of papers focussing on complementary clinical and preclinical aspects of NS, their characterisation, pathophysiological substrates, potential treatment and experimental study. The clinical section embraces 5 papers which: focus on the core features and significance of NS in schizophrenia compared to other disorders (Foussias et al., 2014) ; provide a historical perspective on NS (Malaspina et al., 2014) ; describe established and novel procedures used to measure NS in humans, including clinical trials (Marder and Kirkpatrick, 2014) ; analyse mechanisms underlying the disruption of motivation and anticipatory pleasure (Kring and Figure 1 Negative symptoms throughout the lifespan of schizophrenia. Schizophrenia, which is triggered by a complex pattern of genetic, epigenetic, developmental and environmental factors, is recognised at the moment of the first well-defined psychotic episode (corresponding to positive symptoms). This usually occurs in late adolescence/young adulthood, but there are rare cases of "early-onset" schizophrenia (13-18 years) and even childhood-onset schizophrenia (under the age of 13) (Masi et al., 2006; RapadoCastro et al., 2010) . Once established, remission is rare (perhaps 10-15% of subjects recover after the first episode), and the disease follows a fluctuating course punctuated by psychotic crises. Even when positive symptoms are well treated, NS resist control and many patients display predominantly NS from the first episode on. The term "deficit syndrome" has been used for subjects who manifest predominantly NS (perhaps up to a third in the chronic phase): however, it is not universally accepted and lack of psychosis at first admission suggests that the disorder would not be schizophrenia. In addition to transient and sub-diagnostic psychotic symptoms in many (though not all) high-risk subjects, the prodromal phase is accompanied by prominent NS, as well as impaired social cognition, neurocognitive and mood deficits. Finally, NS like blunted affect predominate in childhood and early-onset schizophrenia. Thus, NS are a poorly-treated and disabling feature throughout the lifespan of schizophrenia. 2014); and discuss the influence on NS of currently-available antipsychotics and newer agents under clinical exploration (Davis et al., 2014) . The preclinical section is subdivided into two subsections. First, readouts for evaluating NS: namely, measures of motivation and reward (Barnes et al., 2014) , and procedures related to social interaction (Wilson and Koenig, 2014) . Second, rodents models for (not of) schizophrenia in which NS-like behaviours have been described, including pharmacological (Neill et al., 2014) , genetic (O'Tuathaigh et al., 2014) and developmental (Moser, 2014) paradigms.
As regards this integrative and introductory paper, it has several objectives. First, to set the scene in summarizing the general features of schizophrenia and its current management, to provide a global overview of the core facets of NS, and to emphasise challenges and opportunities for their improved understanding and control. Second, to specifically review one major theme that intersects with all other chapters yet which is not the topic for any single article. That is, the cerebral circuits and neurochemical substrates underling discrete sub-domains of NS as characterised by structural and functional imaging in humans, as well as electrophysiological and other analytic technologies (Section 3). Third, to interlink the separate contributions of this Volume via a mechanistic framework in which a disruption of frontocortico-temporal and frontocorticostriatal networks, as well as glutamatergic, GABAergic, dopaminergic and oxytocinergic transmission, provides a unifying theme. Fourth, to highlight a number of key topics evoked in the separate articles, and to present some additional aspects not covered elsewhere. Fifth, to discuss prospects for the improved management of NS, with a special emphasis on: (1) Novel pharmacotherapeutic mechanisms, (2) alternative "stimulation" and "cognitivebehavioural-psychosocial" strategies, and (3) the more refined, innovative and broader exploitation of experimental models and readouts for the study of NS. Finally, the present paper incorporates some very recently-published articles (up to March 2014) not otherwise cited in this Special Volume.
2. Clinical studies of negative symptoms: characteristics, prevalence and measurement 2.1. Historical background and core features of negative symptoms up to and including As discussed herein by Malaspina et al. (2014) , NS have a long pedigree in schizophrenia stretching back to the German pioneers of Kraepelin and Bleuler, 19th/early 20th Century English, French and American schools of thought and ultimately perhaps -through Avicenna -to the Hippocratic canon and the father of brain and mind, Alcmaeon of Kroton (Doty, 2007) . In discussing "dementia praecox" (the forerunner term for schizophrenia), Kraepelin was particularly struck by NS-like features of indifference, emotional Table 1 Characteristics of the five major sub-domains of negative symptom.
Sub-domain (alternative terms)
Core characteristics
Blunted affect (affective flattening, blunted expression)
Reduced intensity and range of emotional expression as manifested via vocal and non-verbal modes of communication including intonation (prosody), facial expression, hand-gestures and body movements. Alogia (poverty of speech)
Decreased quantity of speech, reduced spontaneous speech and loss of conversational fluency.
Amotivation (loss of volition)
Deficits in the initiation and maintenance of goal-directed behaviours like work, study, sport, personal hygiene and daily tasks, especially when requiring an effort (cognitive or physical) and significant organisation. Also deficits in desire to undertake such activities. Related to apathy and lack of energy. Anhedonia (reduced ability to experience or anticipate pleasure)
The looking forward to a reward, recreational or other pleasurable experience ("wanting") is more markedly and consistently impaired (anticipatory anhedonia) than the appreciation ("liking") of the experience itself (consummatory anhedonia).
Asociality (social withdrawal)
Diminished interest in, motivation for, and appreciation of social interactions with others, like family and friends. Also, loss of interest in intimate (sexual) relationships independent of any somatic problems. For children, may correspond to loss of interest in playing together.
Deficits indicated are mainly based on a NIMH consensus document (Kirkpatrick et al., 2006) which has been highly influential in orienting research and diagnosis over recent years. As outlined in the text and discussed in detail in this Special Volume (Foussias et al., in press; Malaspina et al., in press; Marder and Kirkpatrick, in press) , there is an emerging consensus, tacitly recognised in DSM-5 and supported by factor analysis, of two sub-clusters of negative symptoms. They comprise: (1) Diminished emotional expression (incorporating blunted affect and -though not explicitly mentioned in DSM-5 -alogia) and (2) avolition (encompassing amotivation, anticipatory anhedonia and asociality). Note that, as compared to poverty of speech itself, impoverished content of speech is now usually integrated into disorganisation, another core domain of schizophrenia specified in DSM-5 ( Figure 3 ). There is a certain degree of overlap and interplay between the five domains: for example, asociality is partially attributable to low social motivation. Further, certain facets of blunted affect, like loss of appropriate speech intonation (prosody) and deficits in non-verbal communication, are also inherent to an impairment of social cognition (Section 2.3).
deficits and, in particular, a lack of volition (Zec, 1995) . Somewhat later, Bleuler (who coined the term schizophrenia) asserted the ability to feel emotion was intact despite a lack of will to seek it out -reminiscent of "anticipatory anhedonia" (Section 3.3) (Heckers, 2011) . He felt that these changes were driven by a core, fundamental and pathophysiological process of disconnectivity (poor associations) of thought and language (Heckers, 2011; Malaspina et al., 2014) . Nonetheless, probably unbeknown to Kraepelin and Bleuler, the notion of "NS" (and positive symptoms) had been foreshadowed by the 19th English neurologist, Reynolds, who, in reference to epilepsy, distinguished symptoms like anaesthesia (loss) from others like spasms (gain) . By analogy, and some 150 years later, in contrast to the positive symptoms of schizophrenia (where delusions and hallucinations etc. are "added"), the term "negative" implies the loss of behaviours, interests, motivation and desires as incarnated by avolition, and "diminished expression" (Table 1 ). As originally conceptualised by Carpenter et al. (1988) , it is desirable (though not always easy) to differentiate primary NS inherent to the disease process itself from secondary NS which may be a consequence of social exclusion, lack of environmental stimulation, a treatment-provoked extrapyramidal syndrome or co-morbid depression etc. (Figure 2 ) (Foussias et al., 2014; Kaiser et al., 2010; Kirkpatrick et al., 2006) . It has been suggested that a "deficit syndrome" associated with a particularly poor outcome and comprising predominately NS can be found in certain drug-naïve patients at the time of admission, and in perhaps a third of chronic schizophrenics (Figures 1 and 2) . Though the status of this "deficit" entity remains somewhat contentious, it is not disputed that many patients display enduring and predominant NS: their inclusion into clinical studies of NS has proven fruitful in the exploration of neurobiological substrates and potential control (Sections 3 and 4) Buchanan, 2007; Carpenter et al., 1988 Carpenter et al., , 1999 Kaiser et al., 2010; Kanahara et al., 2013; Kirkpatrick et al., 2001; Nakaya and Ohmori, 2008; Peralta and Cuesta, 2004; Peralta et al., 2014) .
While NS are firmly established in the firmament of schizophrenia as a core domain of dysfunction (Blanchard and Cohen, 2006; Blanchard et al., 2011; Buchanan, 2007; Messinger et al., 2011) , their composition has evolved significantly, and not always consistently, over the last 30-40 years or so. One important landmark was the National Institute of Mental Health (NIMH), treatment-oriented consensus statement of 2005 (Kirkpatrick et al., 2006) . This document enshrined the following core domains, four of which are prefixed by "a/an", underpinning the abovementioned notion of "loss": anhedonia, asociality, avolition, alogia, and blunted affect (Table 1) . It is worth noting that the additional facet of impaired attention (Andreasen, 1982 (Andreasen, , 1989 was shunted to the sphere of neurocognition where it has become the focus of a complementary NIMH-coordinated initiative to improve neurocognitive deficits and impaired social cognition in schizophrenia (Buchanan et al., 2011b; Carter and Barch, 2007; Millan and Bales, 2013) . While DSM-III tended to neglect negative vs positive symptoms (except for poverty of speech), both avolition and flat affect made their entrance in the revised version DSM-IIIR. Later on, around the turn of the millennium, DSM-IV placed NS on centre stage of the agenda with the recognition of avolition, alogia and blunted affect.
The latter points are thoughtfully discussed by Malaspina et al. (2014) in this volume, who also emphasise that the diagnostic goalposts appear to be moving again with the advent of DSM-5 (Figure 3) Barch et al., 2013; Heckers et al., 2013; Tandon et al., 2013) . In this recently-released tome, NS comprise one of the five "defining" domains of schizophrenia (or schizophrenia spectrum disorder) together with hallucinations (auditory and other sensory sensations not rooted in the outside world), delusions (beliefs detached from reality), disorganised speech (incoherent verbal language) and abnormal psychomotor function (bizarre behaviours and catatonia). In addition to three further (though not "defining") diagnostic dimensions (depression, mania and cognition), NS and the other four core domains of schizophrenia are semi-quantifiable on a scale of 0-4, which should facilitate their assessment and comparison. In the DSM-5 canon, NS are considered to be (1) avolition, embracing decreased motivation, asociality and anticipatory anhedonia and (2) diminished emotional expression, incorporating blunted affect and -implicitly -alogia (poverty of speech) (Table 1) . Avolition would be apparent from, for example, a lack of goal-directed and self-initiated behaviours while restricted emotional expression would be revealed by a poverty of speech and non-verbal (paralinguistic) communication like facial expressions and hand gestures Barch et al., 2013; Heckers et al., 2013; Tandon et al., 2013 Importantly, this lack of non-verbal expression, together with impaired prosody (intonation in speech), intersects with deficits in social cognition (Section 2.3). On the other hand, the "anhedonia" of NS does not, in contrast to depression (a separable domain), principally reflect an ability to experience pleasure ("liking"). Rather, it conforms to deficient anticipation of pleasure ("wanting") as reflected in a lack of coordinated behaviour and effort dedicated to its attainment (Section 3.3) (Berridge et al., 2009; Berridge and Kringelbach, 2013; Der-Avakian and Markou, 2012; Strauss et al., 2014 ) -evocative of the Kraepelian notion of impaired volition (Foussias et al., 2014; Gard et al., 2007; Huxley and Fonseca, 2014; Kaiser et al., 2010; Zec, 1995; Kring and Barch, 2014; Kring and Elis, 2014; Wynn et al., 2010 -but see Konstantakopoulos et al., 2011) . Anticipatory anhedonia is medicationindependent and apparent both at first episode and in the chronic phase of the disorder (Nielsen et al., 2012; Yee et al., 2010) . This issue is carefully analysed by Foussias et al. (2014) , and by the complementary article of Kring and Barch (2014) , in this Special Volume.
These authors likewise discuss the reasoning underlying the growing (and DSM-5 reinforced) conviction of two interrelated yet distinguishable sub-clusters of NS: avolition and diminished emotional expression. This notion harks back to the NIMH consensus document evoked above (Kirkpatrick et al., 2006) and to the analysis made around this time of Blanchard and Cohen, 2006 . Then, and in many subsequent studies (Foussias et al., 2014; Mehta et al., 2011) , the five negative symptom domains summarised in Table 1 could mostly be accounted for by the robust and independent factors of decreased emotional expression and avolition.
Measurement of NS: established and novel rating scales
The above-mentioned distinction has been further reinforced by recent work and, as articulated by Malaspina et al. (2014) and Marder and Kirkpatrick (2014) in this Special Volume, finds expression in the recent development of new rating scales for identification, characterisation and quantification of NS -both in the context of diagnosis and, importantly, of clinical trials. Deserving of special mention are the NIMH-linked CAINS (Clinical Assessment Interview for Negative Symptoms) and the somewhat shorter (time to complete) and already-translated BNSS (Brief Negative Symptom Scale) which: (1) share similar organisation, (2) display excellent test/re-test reliability and (3) provide support for the two-factor concept of deficits in motivation vs blunted affect. These new instruments represent significant advances compared to older scales like the composite and widely-used: (1) Positive and Negative Symptoms Scale (PANSS), of which the relevant subscale fails to fully cover the whole gamut of NS and (2) Scale for Assessment of Negative Symptoms (SANS) which, like the PANNS, incorporates attentional deficits, and conflates observations over a one month period limiting its sensitivity to detect rapid change (Harvey et al., 2006; Horan et al., 2011; Kirkpatrick et al., 2011; Kring et al., 2013; Malaspina et al., 2014; Marder and Kirkpatrick, 2014) . The respective merits -and limitations -of these innovative scales will become clearer in the course of their broader utilisation. In any event, they should permit the more sensitive and rigorous characterisation of NS, with the differentiation of the two above-evoked sub-domains likely related to contrasting neurobiogical substrates (Section 3). This should, in turn, facilitate the clinical evaluation of new and potentially-improved medication for NS (Section 4). Supporting this contention, Strauss et al., 2012 Strauss et al., , 2013 , for example, recently reported two subpopulations that showed contrasting profiles of impaired avolition yet essentially intact expression and vice versa.
Three final yet important points -not enitrely resolved to date by any particular scale per se -should briefly be evoked. These are the issues of, first, differentiating primary NS inherent to the disorder from secondary NS (vide supra). Though reducing NS by avoiding motor sideeffects and alleviating co-morbid depression is obviously desirable, novel medication should be designed to specifically relieve debilitating, primary NS. The second and related issue is distinguishing a symptom from a cause and from an outcome. Social withdrawal, for example, is an expression of asociality and decreased (social) motivation, yet also a consequence of impaired social cognition and a contributory factor to depressed mood. This leads to a third and interrelated remark that NS may have several, converging causes: in the case of social withdrawal, a lack of social motivation, deficits in social cognition and social anxiety. This multiple causation is reflected in the implication of diverse neural substrates discussed in Section 3. Figure 3 Negative symptoms as one of the five diagnostic pillars of schizophrenia in DSM-5. DSM-5 has identified five "defining" symptoms for the diagnosis of schizophrenia, which should become apparent in the course of appropriate observation and interviews. One of these is NS, together with hallucinations and delusions (positive symptoms), psychomotor dysfunction (agitation, retardation, catatonia) and disorganisation. Depressed mood, mania and cognitive impairment (which subsumes impaired social cognition) are additional criteria to be considered, but they are not diagnostic per se. Note that neurocognitive dysfunction usually requires the use of specific tests for its characterisation as opposed to impairment in social cognition and NS which should be apparent during the course of the interview and from other forms of interaction.
Relationship of negative symptoms to impaired social cognition
The concluding point of the previous paragraph brings up the more general, complex and incompletely resolved matter of the interplay between NS and other core domains of dysfunction in schizophrenia in terms of patient phenotype, underlying neurobiological substrates and potential treatment strategies (Figure 4 ). Though normal neurocognitive performance is beneficial for appropriate social cognition, these are distinct domains of function, both of which are impaired in schizophrenia (Bliksted et al., 2014; Brown et al., 2012; Bora et al., 2009; Brüne, 2005; Fanning et al., 2012; Green et al., 2008 Green et al., , 2012 Hoe et al., 2012; Mehta et al., 2013; Millan et al., 2012) . In fact, rather than impaired neurocognition, it is the interface between deficits in social cognition and NS that is the most noteworthy and complex to comprehend since, while distinct, they interact. NS are driven by impaired social cognition which, at least partially, intervenes in its deleterious impact on functional outcome ( Figure 4 ) (Foussias et al., 2014; Harvey et al., 2006; Kaiser et al., 2010; Lincoln et al., 2011; Mehta et al., 2013; Sergi et al., 2007) .
As briefly mentioned above, social cognition refers to the suite of cerebral mechanisms and mental operations used to monitor social signals from others, and to decipher their emotional status and intentions. It embraces "Theory of Mind", the internal representation of the mental state of others in relation to ones own mental state, allowing for the inference of others beliefs, desires, needs, knowledge and future behaviour (Adolphs, 2009; Byrne and Bates, 2010; Frith and Frith, 2012; Millan et al., 2012; Millan and Bales, 2013; Rushworth et al., 2013) . Theory of mind is strongly related to empathy and trust. In humans, social cognition is integrated with culture and verbal language, and necessitates appropriate knowledge of prosody and pragmatics (context-related behaviour and speech) (Fitch et al., 2010; Frith and Frith, 2012; Millan et al., 2012) . Ultimately, effective social cognition is indispensable for appropriate social engagement, social integration, and the setting-up and maintenance of normal social relationships.
As currently conceived, impaired social cognition shows significant overlap with -and may contribute to -NS, so it is not surprising that they involve the anomalous operation of several common neural circuits: notably, the temporal cortex (including the superior temporal gyrus) and the prefrontal cortex (PFC) (Adolphs, 2009; Frith and Frith, 2012; Millan et al., 2012; Rushworth et al., 2013) . Two examples may be given. First, social withdrawal is a consequence both of NS and of faulty Figure 4 The "compass" of schizophrenia: interrelationship between negative symptoms and other core facets of the disorder. In this particular depiction, all roads lead South -to NS, which are comprised of two sub-domains, diminished expression (blunted affect and alogia) and avolition (amotivation, asociality and anticipatory anhedonia), respectively. Reciprocally, NS themselves may feedback to aggravate other facets of schizophrenia. Impaired social cognition is strongly interrelated with, and may drive, NS. For example, social withdrawal is both a feature of NS and a consequence of faulty social cognition. On the other hand, a lack of motivation to engage in social contact will reinforce deficits in social cognition. Deficits in neurocognition, in particular the higher level operations indicated, will aggravate NS, such as mechanisms required for acquisition of reward. The paranoia of positive symptoms may also provoke (secondary) NS. Anxiety is often co-morbid with schizophrenia: it is also provoked by positive symptoms and impending treatment, and may aggravate NS. Further, social anxiety will more directly impact NS, especially social withdrawal. Depression is associated with deficits in effort-related behaviours which, together with anhedonia, will further deteriorate motivation. These observations suggest that NS may, to a certain extent, channel the deleterious influence of other symptoms into poor functional outcome with which NS are strongly correlated. Note that impaired social cognition may also aggravate (provoke) positive symptoms (paranoia and delusions) due to faulty and hasty (jumping to conclusions) interpretation of the actions and intentions of others. Abbreviation not in the text: PAR.CX, Parietal cortex. social cognition -in addition to social anxiety (Pallanti et al., 2004; Romm et al., 2011; Voges and Addington, 2005) . Second, reduced facial expression, body movements and hand gestures are core elements of NS (diminished emotional expression), yet the enactment of these modes of non-verbal communication, just as much as their interpretation, are usually taken as fundamental components of social cognition (Frith and Frith, 2012; Millan et al., 2012) .
One approach to resolving this paradox might be to consider social cognition as purely concerned with the reception and interpretation as opposed to the performance and emission of social signals. For the present purposes, the critical point is that impaired social cognition not only aggravates positive symptoms like paranoia, suspiciousness and delusional thinking, but also contributes to and drives NS (Figure 4 ). This is important since NS and impaired social cognition collectively have the most serious impact upon the functional status of patients: correspondingly, they are correlated with poor outcome throughout the entire course of schizophrenia ( Figure 1 ) (Corcoran et al., 2011; Foussias et al., 2014; Lincoln et al., 2011; Maat et al., 2012; Mehta et al., 2013; Sergi et al., 2007) .
Relationship of negative symptoms to other classes of symptom
The consummatory anhedonia of depression is, as mentioned above, distinct to the anticipatory anhedonia seen in schizophrenia. Nonetheless, co-morbid depression may well exacerbate NS by directly compromising hedonic states, and further delimiting effort-linked cognitive and motor performance aimed at acquiring reward (Harvey et al., 2009; Huxley and Fonseca, 2014; Kaiser et al., 2010; Millan et al., 2012; Salamone et al., 2012) . In a broad sense, anxiety is very prevalent in schizophrenia: in addition to co-morbid anxious states, anxiety can be provoked by psychotic episodes and aversion to medication. Social anxiety is particularly common: it may specifically contribute to social withdrawal, or itself be provoked and aggravated by a lack of social motivation ( Figure 4) (Pallanti et al., 2004; Romm et al., 2011; Voges and Addington, 2005) .
As pointed out elsewhere (e.g., Messinger et al., 2011) , positive symptoms may drive asociality and other facets of NS due to extreme suspiciousness and paranoia. As for neurocognitive deficits, many authors have discussed their interrelationship with NS, and Foussias et al. (2014) considered the possibility that their impact on functional outcome is mainly mediated via NS -and impairment of social cognition (Figure 4) (Harvey et al., 2006; Hoe et al., 2012; Lin et al., 2013; Nakagami et al., 2008; Ventura et al., 2009) . Moreover, Kring and Barch (2014) and Barnes et al. (2014) evoked the significance of compromised executive function and top-down cognitive control (Lesh et al., 2011; Millan et al., 2012) to the defective goal-directed acquisition of reward seen in schizophrenia (Section 3.3). While attentional deficits have, as mentioned above, been detached from NS, this should not detract from the point that impaired attention will deleteriously impact mechanisms sustaining the attainment of reward and social engagement (Figure 4 ) (Der-Avakian and Markou, 2012; Harvey et al., 2006) . In addition, intact episodic memory (remembering, recall, and prospective cognition) (Schacter et al., 2007; Millan et al., 2012) is required for appropriate social interaction and estimation of future reward values (Section 3.3). Reciprocally, avolition can impact multiple domains of neurocognition -not least the performance of cognitive tests during clinical trials (Nakagami et al., 2008; Millan et al., 2012) .
Finally, it is hard to imagine that the poor content of speech and loss of verbal fluency in schizophrenia (a feature of disorganisation) (Figure 3 ) is entirely unrelated to the poverty of speech, itself a sub-domain of NS (Table 1) (Fitch et al., 2010; Frith and Frith, 2012; Millan et al., 2012) .
In light of the above remarks, it is instructive to consider NS not in isolation, but rather in relation to other prominent and interacting symptoms of schizophrenia (Figure 4 ).
Relationship of negative symptoms to functional impairment throughout the lifespan of schizophrenia
In view of the deleterious impact of NS on real world function, it is important to note their occurrence throughout the disorder, not just in medicated, chronic, remittingrelapsing subjects, but around the first episode and even in the prodrome (Figure 1 ) (Boonstra et al., 2012; Corcoran et al., 2011; Demjaha et al., 2012; Fusar-Poli et al., 2013a; Green et al., 2012; . Together with impaired social cognition, co-morbid depression and disorganisation, NS are prominent and disabling in at-risk, prodromal adolescents and young adults (Corcoran et al., 2011; Fulford et al., 2013; Fusar-Poli et al., 2013a Piskutic et al., 2012) . The sub-domains of NS that most disrupt for normal life, social integration and academic achievements in at-risk subjects are uncertain, but intuitively a lack of social motivation is likely to be especially incapacitating.
The presence of NS during the prodrome supports the notion of their primary nature and suggests that NS and their neural substrates may even be a driver (like impaired social cognition) of transition to psychosis (Figure 4) . Correspondingly, it may be hypothesised that treatments alleviating NS -and impaired social cognition/neurocognition -in high-risk young subjects would both alleviate suffering and reduce the risk of transition to schizophrenia -and other serious psychiatric disorders (Fusar-Poli et al., 2013a; Lewis, 2012; Miyamoto et al., 2012; Millan et al., 2012; Sabbag et al., 2011). 2.6. Negative-like symptoms in other psychiatric and neurological disorders
The present issue focuses exclusively on schizophrenia but it is worth accentuating, as exemplified in the article of Foussias et al., 2014 , that NS-like symptoms are present in several other psychiatric and neurological disorders. This mirrors the occurrence of deficits in social cognition across a broad range of psychiatric and neurological conditions and emphasises that NS alone cannot per se be considered as diagnostic for schizophrenia ( Figure 3) Tandon et al., 2013) . It has been claimed that NS (including apathy) are manifest in about a third of subjects with major depression, and that they are distinct from consummatory pleasure (anhedonia) (Bottlender et al., 2003; Huxley and Fonseca, 2014) . Apathy is also prominent in Parkinson's and Alzheimer's disease and, in the latter case, correlates with the magnitude of dementia (Chase, 2011; Levy and Dubois, 2006; Millan, 2010; Mitchell et al., 2011; Starkstein et al., 2009 ). Mirroring schizophrenia, the presence of NS in these disorders is associated with poor functional status, and conventional medication is largely ineffective (op. cit).
Certain mechanisms underlying NS may be similar between schizophrenia and other disorders, such as the anomalous operation of cortico-striatal mechanisms of reward, yet others will inevitably differ (Berridge and Kringelbach, 2013; Gradin et al., 2011; Kring and Barch, 2014; Simon et al., 2010) . For example, the implication of anomalous dopaminergic signalling in the apathy of both schizophrenia and Parkinson's disease deserves mention, as well as a role for dysfunctional circuits linking the PFC and the basal ganglia (Section 3) (Chase, 2011; Levy and Dubois, 2006; Starkstein et al., 2009) . Conversely, as regards anhedonia, the perturbation of mesolimbic dopaminergic transmission in major depression can be differentiated from its deregulation in schizophrenia (Section 3.3) (Millan, 2006; Remington et al., 2011) . Further, despite the fact that aberrant function of the PFC is incriminated in the apathy of schizophrenia and Alzheimer's disease (Section 3.2), the functional breakdown of frontocortico-temporal coupling in schizophrenia (Section 3.1) can be distinguished from the progressive β-amyloid and tau-driven processes of neuronal neurodegeneration that damage the temporal lobe and entorhinal cortex in Alzheimer's disease (Chase, 2011; Mitchell et al., 2011; Stella et al., 2014) .
Importantly, common patterns of NS-like symptoms -and pathophysiological substrates -amongst schizophrenia and other diseases accentuate the relevance of a transnosological perspective in the study and ultimately control of multi-factorial and heterogeneous disorders like schizophrenia (Cuthbert, 2014; Millan et al., 2012 ). An agent found to alleviate NS in schizophrenia might emerge to have broader utility in the treatment of NS-like symptoms in other psychiatric and neurological disorders.
3. Neural and neurochemical substrates of negative symptoms 3.1. Cortico-subcortical circuits implicated in NS: general considerations By analogy to Alzheimer's disease, there has been some debate as to whether schizophrenia might, at least partially, be a neurodegenerative-like disorder, with "neurotoxic" repercussions of the disease process itself progressively damaging the brain in a manner, either inhibited by, resistant to, or even exacerbated by antipsychotics (Archer, 2010; Fusar-Poli et al., 2013b; Rund, 2009) . Nonetheless, there is overwhelming evidence that schizophrenia is principally a disorder of neurodevelopment triggered by a panoply of genetic, epigenetic and environmental factors, providing a the foundation for animal models discussed in Section 5 (Archer, 2010; Fatemi and Folsom, 2009; Millan, 2013; Puri, 2010; Rapoport et al., 2012) .
Regardless of causation, as described below, like other facets of schizophrenia, NS likely reflect anomalies of distributed neural networks rather than the disruption of any discrete brain region ( Figure 5 ). The corresponding structural and functional changes are well-established at the time of the first psychotic episode, and they actually anticipate diagnosis bring prominent in high-risks subjects prior to transition (Section 2.5): further, they continue to progress throughout the course of the disorder, notably as regards changes in the frontal and temporal lobes (FusarPoli et al., 2012 (FusarPoli et al., , 2013b Nakamura et al., 2013; Puri, 2010; Vita et al., 2012) .
Many investigations have compared patients displaying persistent and predominant NS to those without them, or studied patients with a "deficit syndrome" (Section 2.1) (Carpenter et al., 1988 (Carpenter et al., , 1999 Buchanan, 2007; Kaiser et al., 2010; Kirkpatrick et al., 2001) , in order to pinpoint the key circuits impacted. As regards techniques exploited, structural Magnetic Resonance Imaging (MRI) imaging permits visualisation of alterations in the grey matter volume of specific brain structures, Diffusion Tensor Imaging has been employed to examine the disruption of white matter tracts, and functional neuroimaging -mainly functional MRI (fMRI), but also Single Photon Emission Computerised Tomography (SPECT) -has been applied to probe the alterations in neuronal activity of discrete brain regions in relation to NS.
Several studies of schizophrenia outlined below have focussed on the resting and self-referential "default mode network", which deactivates during goal-directed activitysuch as the organised acquisition of a reward (Broyd et al., 2009; Mazza et al., 2013; Orliac et al., 2013; Park et al., 2009; Whitfield-Gabrieli and Ford, 2012) . Nonetheless, most fMRI work has been undertaken employing cognitive tasks, of which certain -like executive function -are coordinated by cortico-subcortical networks dysfunctional in NS. In addition, studies of blunted affect have tended to exploit emotionally-charged (and erroneously interpreted) stimuli to determine the sites of anomalous cerebral activity in schizophrenia Dowd and Barch, 2010; Goghari et al., 2010; .
For all studies, despite an increasing tendency to perform work early in the disorder and in subjects with predominant NS, it is still difficult to isolate changes directly related to NS vs those coupled to other symptoms, in particular as regards impaired social cognition (Section 2.3). Studies have been undertaken in drug-naïve subjects, but medication remains an obvious confound: in this case, an attractive option is to examine its potential reversal of putative anomalies Benoit et al., 2012; Filippi et al., 2014; Goghari et al., 2010; Kring and Barch, 2014; Stip et al., 2005; Strauss et al., 2014) .
As regards the interpretation of data, it should not automatically be assumed that alterations are causal to NS: changes may be merely correlated (epiphenomon) or even provoked by NS themselves. Alternatively, they may be compensatory in an effort to counter the deleterious impact of NS, as suggested for cannibinoids (Section 3.7) (Ceccarini et al., 2013) and exemplified by observations in schizophrenics that certain brain regions are over-activated in cognitive, emotion-processing and motor procedures in an attempt to offset the failure of structures that fail to respond (Bracht et al., 2014; Koike et al., 2013; Taylor et al., 2012; Unschuld et al., 2014) . Moreover, from a transnosological perspective, it is still unclear which cerebral mechanisms implicated in the NS of schizophrenia are entirely distinct from those incriminated in the NS-like dysfunction of other disorders (Section 2.5). Finally, pathophysiological mechanisms incriminated in the genesis of NS are not necessarily synonymous with those that maintain them once established.
Despite these caveats, and sometimes marked variability between the findings of specific studies, data from complementary structural, imaging and electrophysiological approaches have converged in incriminating several pivotal networks and cerebral structures in NS. Further, the conclusions of studies in patients are globally in line with experimental work discussed below, despite the -to date -limited application of imaging to rodents (Section 5). As outlined below, fronto-temporal and frontocortico-striatal circuits are the most consistently and robustly implicated in NS -though not exclusively -but the roles of their specific sub-regions differ amongst distinct sub-domains of NS.
It is instructive to initially summarise overall findings for the temporal and frontocortical lobes before focussing on structures more specifically implicated in the different subdomains of NS. The dysfunction of neural networks involved in anticipatory anhedonia is particularly complex and authoritively analysed by Kring and Barch (2014) in this Special Volume. Consequently, this rich and specialised body of the literature is only succinctly summarised below.
3.2. Anomalies of cerebral structures implicated in NS: structural and functional characterisation 3.2.1. Temporal lobes: structural imaging A decrease in the grey matter volume of the temporal lobe, in particular the superior temporal gyrus, has been associated with NS with striking consistency (Benoit et al., 2012; Cascella et al., 2010; Fischer et al., 2012; Fusar-Poli et al., 2012 , 2013b Galderisi et al., 2008; Sanfilipo et al., 2000; Vita et al., 2012; Yamasue et al., 2004) . Interestingly, the temporal gyri lie at the heart of circuits involved in social cognition, including facial/gaze processing and, for the superior temporal gyrus, Theory of Mind -and this region is also integral to networks integrating language (Adolphs, 2009; Carrington and Figure 5 Schematic representation of cerebral circuits impacted in NS, in particular in relation to deficits in anticipatory reward. As discussed in the text, a perturbation of frontocortico-temporal networks has been consistently related to NS, while a disruption of cortico-striatal loops is strongly implicated in amotivation and anticipatory anhedonia. As depicted, these sub-domains of NS reflect the impaired operation of several, anatomically-and functionally-distinct (yet interdependent and interacting) pathways running from the prefrontal cortex (PFC) to the dorsal or ventral striatum. From the latter regions, pathways project to sub-regions of the pallidum which, via the thalamus and dopaminergic nuclei of the ventrotegmental area (VTA), close the loops in projecting back to the PFC. The nucleus accumbens, itself also under the influence of the amygdala, is a core region for modulation of reward and emotional processing. Several other cerebral regions implicated in NS are not shown for reasons of space (see text), and the thalamus has been anatomically relocated for better visibility. Glutamatergic fibres interconnecting the various territories of the PFC are not shown for reasons of clarity, nor projections from the PFC to the VTA. Many neurotransmitters are implicated in NS, as highlighted for amotivation/anticipatory anhedonia in the inset. Abbreviations not in the text: ACC, anterior cingulate cortex; STG; superior temporal gyrus; GP, Globus pallidus; VP, Ventral pallidum; SNpc, Substantia nigra, pars compacta; OT, Oxytocin and Glu, glutamate CB. et al., 2013) . These observations are consistent with the reduced verbal expression (alogia) of NS and underscore the interrelationship of NS with impaired social cognition, though temporal lobe anomalies are also related to other features of schizophrenia, like positive symptoms and disorganisation (Goghari et al., 2010) .
The temporal lobe is strongly interconnected with the frontal lobes, and both structural studies of white matterand electrophysiological recordings (Section 3.2.4) (Kim et al., 2014 , Thoma et al., 2005 -suggest that the disruption of this connection is related to the genesis of NS. For example, the uncinate fasiculus links the temporal lobe to the orbitofrontal cortex (OFC), and its disturbance in schizophrenia has been related to NS, perhaps due to interrupted exchange of information concerning reward value and history (Kitis et al., 2012 ; S.H. Nestor et al., 2013; Voineskos et al., 2013; Von Der Heide et al., 2013) .
There is, then, a compelling set of observations linking dysfunction of the temporal lobe to NS, most likely as regards asociality and blunted affect (especially alogia) and perhaps also as concerns the elements of time and memory for predicting reward, though this remains to be directly demonstrated.
Frontal lobes: structural imaging
As for the frontal lobes themselves, a rather disparate pattern of grey matter reductions has been found in various sub-regions .
Regions where deceases in grey matter have been reported include the inferior frontal gyrus -a core component of social cognition (Adolphs, 2009; Millan et al., 2012 ) -and both the OFC and anterior cingulate, with a probable link to aberrant mechanisms of reward (Bergé et al., 2011; Filippi et al., 2014; Galderisi et al., 2008; Nakamura et al., 2013; Nestor et al., 2013; Sanfilipo et al., 2000; Schobel et al., 2009; Stip et al., 2005; Takayanagi et al., 2010 Takayanagi et al., , 2013 Yamasue et al., 2004) . Conversely and counter-intuitively, despite its implication in deficient goal-directed behaviour required for reward acquisition (Kring and Barch, 2014) , the dorsolateral PFC (DLPFC) has shown only modest and variable changes in volume: moreover, putative changes are not necessarily correlated with NS, rather to cognitive dysfunction (Baaré et al., 1999; Behere, 2013; Benoit et al., 2012; Fischer et al., 2012; Galderisi et al., 2008; Schobel et al., 2009; Stip et al., 2005; Takayanagi et al., 2010; Volpe et al., 2012) .
A rather robust observation is a reduction of white matter, correlated with the severity of NS and suggesting reduced connectivity: (1) amongst sub-territories of the PFC, (2) between the PFC and other cortical regions like the temporal, insular and occipital cortices (see above) and (3) to sub-cortical structures like the striatum (see below) (Bracht et al., 2014; Cascella et al., 2010; Galderisi et al., 2008; Hoe et al., 2012 ; S.H. Voineskos et al., 2013; Zetzsche et al., 2008) .
Temporal and frontal lobes: functional imaging
Reinforcing structural data presented above, functional imaging has visualised temporal lobe anomalies linked to NS, including hypoactivity and a greater rightward symmetry: aberrant operation of the temporal lobe is also suggested by the poor performance of schizophrenics in neuropsychological tests involving the temporal cortex. In addition, NS are correlated with reduced connectivity of the superior temporal gyrus to frontocortical regions like the anterior cingulate (Benoit et al., 2012; Cohen et al., 2007; Ke et al., 2010; Millan et al., 2012; Potkin et al., 2002) .
As concerns the PFC itself, several studies suggest that a dysfunction of the default mode network involving the ventromedial PFC is correlated with NS Orliac et al., 2013; Park et al., 2009) , and possibly defective verbal expression (Bluhm et al., 2007; WhitfieldGabrieli and Ford, 2012) . Further, there are reports of abnormal activity in the OFC and anterior cingulate, changes blunted by antipsychotics (Kanahara et al., 2013; Stip et al., 2005) . Similar alterations have been seen in the insula, and its interaction with the anterior cingulate appears to be disrupted in schizophrenia ( Figure 5 ) (Gradin et al., 2013; Manoliu et al., 2013) .
Mirroring findings with structural studies evoked above, and in contrast to the ventromedial PFC ( Figure 5 ), fMRI studies have not invariably found an association between NS and decreased operation of the DLPFC: disruption of this region and its interaction with the striatum seems more strongly linked to disorganisation and cognitive impairment, notably of executive function (Ehrlich et al., 2012; Goghari et al., 2010; Lesh et al., 2011; Van Veelen et al., 2010) . Goghari et al. (2010) carefully discussed these findings, and suggested that putative deficits in DLPFC activity may have been normalised by antipsychotics in certain studiesanalogous to above-mentioned findings for the OFC and anterior cingulate . Interestingly, disruption of DLPFC activity (and frontal lobe dysfunction in general) was claimed to be predictive of the induction of NS by ketamine (Honey et al., 2008) . Clearly, the question of how the apparent dysfunction of the DLPFC in schizophrenia relates to NS awaits more refined evaluation.
It should also be pointed out that alterations in the activity and connectivity of the parietal cortex, including the precuneus -part of the default mode network (Whitfield-Gabrieli and Ford, 2012) -have been linked to the induction of NS (Bluhm et al., 2007; Broyd et al., 2009; Goghari et al., 2010) . It is possible that these observations relate to the important role of this region in social cognition (Adolphs, 2009; Millan et al., 2012; Guo et al., 2014; Rushworth et al., 2013) .
Thus, the interplay between NS on the one hand and neurocognition-social cognition on the other can be hard to determine. Nonetheless, structural and functional data collectively indicate that a disruption of diverse subterritories of the temporal lobe and PFC, and of communication between the PFC, temporal and probably insular, parietal and occipital lobes, is related to NS. As indicated below, this is not to neglect the significance of PFC coupling to the basal ganglia, and the possible implication of other structures like the thalamus and cerebellum (Ehrlich et al., 2012; Goghari et al., 2010; Pinault, 2011; Potkin et al., 2002) .
Cortical and sub-cortical circuits, electrophysiological studies
Though perhaps less glamourous than imaging, noninvasive electrophysiological (EEG) tools are invaluable for characterising the interrelationship between the activity of specific cerebral circuits and functional domains perturbed in schizophrenia like information-processing, mood and cognition, (Boutros et al., 2013; Millan et al., 2012; Wang, 2010) .
It was suggested that an impairment in the synchronous operation of local vs global cortical circuits, including a loss of gamma power, is specifically linked to NS (Noh et al., 2013) . This is interesting since the coordination of PFCdriven glutamatergic networks by GABAergic interneurones can be picked up in the gamma range (30-80 Hz): their disruption in schizophrenia is related to abnormal, PFCintegrated executive function and "top-down control" which indirectly impacts NS (Figures 4 and 5) (Kring and Barch, 2014; Stan and Lewis, 2012; Lesh et al., 2011; Millan et al., 2012; Wang, 2010) . Likewise of pertinence are studies using spectral EEG that related increases in slower rhythms, including episodic memory-related, frontocorticohippocampal theta (4-7 Hz), to the intensity of NS (Boutros et al., 2013) . Further, a decrease in delta slow wave sleep has repeatedly been found to correlate with NS severity; it appears to involve perturbation of thalamic projections to the frontal lobes, emphasising that aberrant input to the cortex from this key gating structure may participate in the induction of NS (Pinault, 2011; Sekimoto et al., 2011) .
The monitoring of Event Related Potentials (ERP) can also yield insights into the integrity of cortical circuits in relation to NS and to the risk of transition during the prodromal phase (Boutros et al., 2013; Fusar-Poli et al., 2013a; Horan et al., 2010) . For example, several -though not all -studies indicate that interference with the P300 "oddball" (unexpected stimulus) response is linked to NS: further, the most marked reduction is seen over the parietal region in patients with predominantly NS, as opposed to the temporal lobe for those with less pronounced NS (Boutros et al., 2013; Oribe et al., 2013; Ozgürdal et al., 2008) . The P300 signal is already aberrant in subjects at high risk for conversion (Boutros et al., 2013; Fusar-Poli et al., 2013a) . As another example, studies of ERP have supported the above-evoked relationship between fronto-temporal decoupling and NS (Kim et al., 2014; Thoma et al., 2005) .
The precise mechanistic foundations of links between electrophysiological readouts on the one hand, and NS on the other, is still uncertain, but these findings reinforce the significance of disruption of cortical and cortico-subcortical networks to their genesis.
Dysfunctional neural circuits related to amotivation and anticipatory anhedonia
As emphasised in this Special Volume (Foussias et al., 2014; Kring and Barch, 2014; Malaspina et al., 2014) , the appreciation of pleasure per se does not seem to be greatly affected in schizophrenia, and consummatory anhedonia ("liking") appears to be dissociable from NS which are coupled to compromised "wanting" (anticipatory anhedonia) (Berridge et al., 2009; Berridge and Kringelbach, 2013; Huxley and Fonseca, 2014) . Imaging studies support this interpretation, despite the fact that some variable changes have been seen in fMRI studies of the response of the cortex, striatum, cerebellum and amygdala to rewarding stimuli Barch and Dowd, 2010; Goghari et al., 2010; Kring and Barch, 2014; Simon et al., 2010) .
By contrast to consummatory pleasure per se, imaging studies in schizophrenics have consistently revealed anomalies in processes related to the anticipation of reward (anticipatory anhedonia), and to the motivation, effort, approach behaviour and goal-directed actions requisite for acquisition: they can primarily be attributed to abnormal operation of the ventral striatum (nucleus accumbens) and dorsal striatum (mainly the caudate) in interaction with the PFC (Figure 5 ). For example, cues signalling reward are less efficient in activating the ventral striatum -and ventromedial PFC/OFC -in schizophrenics (Dowd and Barch, 2012; Juckel et al., 2006; Harvey et al., 2009; Nielsen et al., 2012; Simon et al., 2010; Strauss et al., 2014; Waltz et al., 2009 ). Other interlinked structures also appear to be involved, like the anterior insular cortex which projects to the OFC and ventral striatum and which is reciprocally interconnected with the amygdala: it plays an important role in social cognition, emotional processing, mood and reward, and both its volume and functional activity is compromised in schizophrenia (Section 3.1) Manoliu et al., 2013; Waltz et al., 2009; Yamasue et al., 2004) , with a specific link to the reward deficits of NS (Croxson et al., 2009; Dowd and Barch, 2010; Gradin et al., 2011) .
Since the article of Kring and Barch (2014) in this Special Volume (Section 5.6) critically analyses this sub-domain of NS in detail, the core observations are only briefly recapitulated below and, for ease of comprehension, the major circuits implicated are graphically presented in Figure 5 . See also Barnes et al. (2014) in this Special Volume for an experimental perspective on this issue, and note that anatomical and functional observations are not entirely transposable across species.
The motivational deficits accounting for anticipatory anhedonia -or impaired anticipatory pleasure (desire) -can be parsed into several, interrelated functions known to be compromised in schizophrenia (Croxson et al., 2009; Fervaha et al., 2013; Gold et al., 2013 , Strauss et al., 2014 Ward et al., 2012) , and mediated by contrasting territories of the PFC and striatum ( Figure 5 ).
First, a core element of motivation is the perceived value of the reward in relation to desires/needs. This may need to be updated in the light of recent experience, and value calculated in light of the delay to receipt ("delay discounting"). The OFC -which plays a key role with the nucleus accumbens in pleasure (Berridge and Kringelbach, 2013; Kringelbach, 2005) -acts in interaction with the nucleus accumbens and dopaminergic mechanisms to underpin these functions (Deserno et al., 2013; Padoa-Schioppa and Cai, 2011) . Both the function of the OFC and its interconnection with the nucleus accumbens, as well as value computation of reward, are perturbed in schizophrenia (Bracht et al., 2014 , Diekhof et al., 2012 Harvey et al., 2009; Levy and Dubois, 2006; Morris et al., 2012; Strauss et al., 2014) . Faulty encoding of expected reward in schizophrenia (implicated in apathy) involves, then, dysfunction of an OFCstriatal network, though other DA-rich regions may also be involved, like the insular cortex, amgydala and hippocampus (Gradin et al., 2011; Kring and Barch, 2014; Levy and Dubois, 2006) . Second, acquiring a reward necessitates effort and will incur a (cognitive and/or physical) cost, the computation of which is assumed by the anterior cingulate together with (dopaminergic signalling in) the nucleus accumbens. Their functional integrity is essential for a decision to opt for a greater reward coupled to supplementary effort, and patients with schizophrenia show both a disruption of the anterior cingulate (Section 3.2) and of this function (Botvinick et al., 2009; Croxson et al., 2009; Fervaha et al., 2013; Gold et al., 2013 Treadway et al., 2009 Treadway et al., , 2012 Ward et al., 2012) . Interestingly, in a social environment, it may be necessary to compete for reward, coupled to additional effort, and the anterior cingulate likewise appears to be involved in option selection in this context, one likely to be flawed in schizophrenia (Hillman and Bilkey, 2012) . It should also be mentioned that dysfunctional coupling between the anterior cingulate and the insular cortex ("salience network") has been linked to the failure to appropriately process reward in schizophrenia (Gradin et al., 2013) .
Third, in the context of exploratory behaviour, a goaldirected action must be engaged in order to obtain the reward, This function appears to depend on the DLPFC which, reflecting intrinsic dopaminergic, adrenergic and other mechanisms related to executive function, exerts a top-down control to enhance reward oriented behaviour (Lesh et al., 2011; Levy and Dubois, 2006; Millan et al., 2012) . The abnormal activity of the DLPFC in schizophrenia (Section 3.2) relates, then, in conjunction with impaired executive function (coordination, planning, organisation), to deficits in the initiation and maintenance of goaldirected, reward-seeking behaviour and its appropriate linking to affect (Goghari et al., 2010; Kring and Barch, 2014; Millan et al., 2012; Strauss et al., 2013; Unschuld et al., 2014; Ursu et al., 2011; Van Veelen et al., 2010) .
The above observations collectively provide a framework for conceptualising the amotivation and anticipatory anhedonia of NS not as a loss of hedonic state and reward appreciation as such, but rather in terms of defective cortico-striatal integrated processes indispensable for reward acquisition and anticipatory pleasure. These deficits are interlinked with anomalies in emotional processing and neurocognitive operations related to executive function and episodic memory (recalling previous positive experiences and prospective imaging of future pleasure), in line with the involvement of other structures like the temporal lobe, insular cortex, amygdala and hippocampal complex (Gradin et al., 2011; Schacter et al., 2007; Millan et al., 2012; Ursu et al., 2011) .
In a nutshell, schizophrenic patients are unable to assemble, get motivated by and exploit information about previous pleasurable experiences in the service of goaldirected and effort-requiring attainment of a future reward (Burbridge and Barch, 2007; Deserno et al., 2013; Kring and Barch, 2014; Strauss et al., 2014) .
Dysfunctional neural circuits related to asociality
As regards a further sub-domain of NS, asociality, the relevant structures disrupted in schizophrenia are less well delineated than those underpinning anticipatory anhedonia, and it is hard to tease them apart from those implicated in impaired social cognition. Nonetheless, inasmuch as asociality is, at least partially, driven by a lack of (anticipatory) social motivation, asociality presumably involves mechanisms and substrates outlined in the previous paragraphs. Indeed, a role of the nucleus accumbens (striatum) in social anhedonia has been evoked . Additional neural structures are also likely to be incriminated as deduced by studies in humans, by experimental work in rodents and, in both cases, by studies of the "prosocial" neuropeptide, oxytocin (Sections 3.6 and 4.8).
Thus, the disruption of an oxytocin-modulated network incorporating the superior temporal gyrus, inferior frontal gyrus, PFC and insula cortex, may contribute to social withdrawal in schizophrenia (Churchland and Winkielman, 2012; Millan et al., 2012; Millan and Bales, 2013; MeyerLindenberg et al., 2011) . Further, oxytocin promotes social behaviour and social motivation via actions in the nucleus accumbens and amygdala (Dolen et al., 2013; Gordon et al., 2011; Lee et al., 2005 Rosenfeld et al., 2011 , and anomalous cannibinoidergic signalling in these regions, in interaction with the PFC, may also be involved in the loss of sociality in schizophrenia (Seillier et al., 2010 (Seillier et al., , 2013 Trezza et al., 2011a Trezza et al., , 2011b . These neurochemical observations, further evoked below (Section 3.6), support a role for anomalous operation of frontocortico-subcortical circuits in the asociality of schizophrenia.
In addition, it might be speculated that a failure of the default mode network to properly deactivate when switching from a self-referential to a social context, may contribute to impaired social engagement in schizophrenia (Bluhm et al., 2007; Broyd et al., 2009; Whitfield-Gabrieli and Ford, 2012; Mazza et al., 2013; Orliac et al., 2013) .
Dysfunctional neural circuits related to diminished emotional expression
By analogy to asociality, information on the precise neural substrates underlying diminished emotional expression also remains fragmentary though loss of the expressive use of non-verbal signals like hand gestures likely involves structures common to impaired social cognition (vide supra).
Furthermore, a complete dissociation of neural substrates implicated in avolition compared to those involved in blunted affect would seem improbable. In addition to roles for the ventromedial PFC, DLPFC, anterior cingulate and temporal cortex, impaired emotional processing and expression in response to positive and negative emotional stimuli may be related to anomalous activation of the amygdala, and to changes in the dorsal striatum and hippocampus/parahippocampal gyrus Kring and Elis, 2014; Fahim et al., 2005; Goghari et al., 2010; Gur et al., 2007; Lepage et al., 2011; Rosenfeld et al., 2011; Taylor et al., 2012; Ursu et al., 2011) . A link between dysfunctional language-speech networks incorporating the PFC, temporal, parietal and occipital cortices and poor content of speech appears probable (Makris et al., 2010; Millan et al., 2012; Poeppel, 2012) , but the specific neural foundations of alogia (decreased verbal fluency) are not well understood Potkin et al., 2002) .
Finally, alterations in default mode activity and connectivity of the ventromedial PFC and parietal cortex may be linked to decreased verbal expression (Bluhm et al., 2007; Orliac et al., 2013; Whitfield-Gabrieli and Ford, 2012) .
Further work remains to be undertaken to better define the specific neural substrates implicated in the diminished emotional expression of schizophrenia.
Onset of anomalies related to NS in at-risk patients prior to diagnosis
To summarise, while many questions persist, anomalous operation of a complex suite of partially-overlapping and interacting cortico-subcortical circuits is implicated in the various sub-domains of NS, and certain are common to impaired social cognition. A broad role of the PFC in interaction with the temporal cortex, striatum and amygdala can be recognised, yet distinct sub-territories fulfil differential roles, accounting for the contrasting functional impact of their dysfunction. In addition, the significance of interacting regions like the insular and parietal cortices, as well as the thalamus and cerebellum, should not be neglected.
The earliest circuit irregularity antecedent to schizophrenia -assuming it exists -is not currently known, nor whether it might act as a trigger for the complex pattern of disruption related to NS. In this light, the increasing application of imaging early in the disorder, during the prodrome, and in young subjects with identified risk factors, should progressively clarify the comparative time of emergence of diverse neural anomalies linked to NS sub-domains.
Importantly, mirroring NS themselves, the underlying structural, functional and electrophysiological changes are manifest in at-risk and prodromal subjects and hence anticipate the first psychotic episode (Section 2.5). Notably, even before diagnosis, grey matter volume reductions, white matter changes and network disruption are seen in structures like the PFC, temporal and insular cortices (Fusar-Poli et al., 2012 , 2013b Smieskova et al., 2012) , together with perturbation of ERP depending upon frontotemporal-parietal circuits (Boutros et al., 2013; Kim et al., 2014; Oribe et al., 2013; Ozgürdal et al., 2008) . These points are of significance with respect to the development of potential biomarkers for predicting transition of vulnerable individuals to schizophrenia.
From neural substrates to cellular and neurochemical bases of NS
Another important question -which bears on the chronology of pathophysiological changes triggering NS -concerns the molecular substrates of neural circuit dysfunction in schizophrenia.
Various sub-domains of NS may be independently provoked by contrasting cellular anomalies, such as aberrant oxytocinergic transmission for asociality, or anomalous cannabinoid/DA signalling for anticipatory anhedonia. On the other hand, abnormal expression of proteins like Reelin or Neuregulin-1 would impact a broad community of GABAergic interneurons and cortical pyramidal neurones dispersed across multiple regions of the PFC implicated in NS: furthermore, the induction of an immune-inflammatory response upon perinatal infection would likewise have a widespread impact on the developing brain (Fatemi and Folsom, 2009; Lewis, 2012; Millan, 2013; Moser, 2014; Piontkewitz et al., 2012; Rapoport et al., 2012) . It remains then to be clarified just how the various patterns of neuronal and circuit dysfunction linked to sub-domains of NS are interrelated in terms of their causes, interplay and onset, and whether there exists a unifying and common precipitating mechanism.
To determine the succession of events that ultimately result in NS and schizophrenia itself, it will be necessary to considerably improve our knowledge at the cellular level. Compared to the rich pattern of data generated concerning neural circuits, little is known at the neurotransmitter level regarding NS since it is technically far more challenging to undertake such studies on humans as compared to the conventional imaging. Nevertheless, the following findings -generally supported by experimental observations (Section 5) -justify mention.
Magnetic Resonance Spectroscopy data has provided direct evidence that a disruption of GABA-glutamatergic dialogue in the PFC and striatum is correlated with NS, though a disequilibrium of the inhibitory-excitatory balance is also related to neurocognitive and positive symptoms (Poels et al., 2014; Reid et al., 2010; Rowland et al., 2013) . The endogenous antioxidant, glutathione, interacts with NMDA receptors and may protect against the induction of schizophrenia (Yao and Keshavan, 2011) , so it is of note that decreases in its levels correlate with the severity of NS (Matsuzawa et al., 2008) .
Positron Emission Tomography (PET) and SPECT permit the characterisation of dopaminergic transmission in terms of DA release and receptor occupation (Mugnaini et al., 2013) and, as outlined by Kring and Barch (2014) and Barnes et al. (2014) , convergent clinical and preclinical evidence support the core significance of aberrant striatal and prefrontal dopaminergic signalling in the motivational deficits of schizophrenia (Section 3.2). An interesting variant on these data, and an approach that could be more widely used to examine neurochemical substrates of NS, is provided by the finding that repetitive Transcranial Magnetic Stimulation (TMS) of the PFC -which can relieve NS (Section 5.5) -elicits DA release in the human caudate (Stratella et al., 2001) . It should also be mentioned that a comparatively early deficit in mesocortical dopaminergic transmission related to NS and cognitive impairment -itself downstream of aberrant GABA-glutamate coupling -may secondarily provoke the hyperactivity/hyper-responsiveness of mesolimbic dopaminergic pathways manifested in positive symptoms at the time of the first psychotic episode (Lewis, 2012; Millan et al., 2012; Remington et al., 2011) .
Especially intriguing are data pertaining to endogenous cannabinoids in view of their role in reward mechanisms expressed in the mesolimbic system in interaction with dopamine (Der-Avakian and Markou, 2012; Leweke, 2012; Leweke et al., 2012) . Cerebrospinal fluid levels of the endogenous ligand, anandamide, are elevated in schizophrenia. Similarly, the density of Cannibinoid (CB) 1 receptors is higher in post-mortem tissue, and several studies have found comparable increases in CB1 receptor number in the nucleus accumbens and PFC using highly-selective PET ligands. Importantly, increases in CB1 receptor signalling in the nucleus accumbens (and other structures) are negatively correlated with NS. Accordingly, even though cannabis abuse is a risk factor for psychosis, it has been speculated that endogenous cannibinoidergic mechanisms play a counter-adaptive and protective role in the suppression of NS (Ceccarini et al., 2013; Coulston et al., 2011; Leweke et al., 2012) . This line of thinking will be of interest to pursue.
Finally, to reiterate a point outlined above, decreased oxytocinergic transmission appears to be implicated not only in impaired social cognition but also in the genesis of NS, including a loss of social motivation and interaction (Churchland and Winkielman, 2012; Goodson and Thompson, 2010; Gordon et al., 2011; Meyer-Lindenberg et al., 2011) . That oxytocinergic signalling is defective in schizophrenia is suggested by the modest correlation between reduced cerebrospinal fluid and plasma levels of oxytocin and the magnitude of NS (Goodson and Thompson, 2010; MeyerLindenberg et al., 2011; Rosenfeld et al., 2011; Rubin et al., 2010; Sasayama et al., 2012) . Though this relationship would benefit from confirmation, a significant associations has been reported between Single Nucleotide Polymorphisms in the Oxytocin receptor gene and NS (Montag et al., 2013) . There is experimental evidence that an interaction with serotonergic transmission in the nucleus accumbens participates in the facilitation of social behaviour and reward by oxytocin (Dolen et al., 2013) , while oxytocin also acts in the amygdala to favour social behaviour and motivation (Gordon et al., 2011; Lee et al., 2005 Rosenfeld et al., 2011 . Hence, deficient oxytocinergic transmission in these regions, and in cortico-subcortical circuits underpinning social cognition and processing (Section 3.3) (Meyer-Lindenberg et al., 2011) . may be related to the asociality of schizophrenia.
Other mechanisms potentially defective in schizophrenia should also be briefly evoked. These include mu-opioid receptors which in the nucleus accumbens and in interaction with DA, facilitate social and other mode of reward, while kappa-opioid receptors act oppositely: further, likewise acting in this region, adenosine regulates rewardrelated effort (Chartoff et al., 2012; Salamone et al., 2012; Scholsburg et al., 2013; Trezza et al., 2011a Trezza et al., , 2011b .
Implications of insights into neural and neurochemical substrates of NS for novel modes of treatment
As summarised in the preceding section, our knowledge of neurochemical substrates underpinning NS remains patchy, and this restricted knowledge base continues to handicap the elaboration of novel medication (Section 4). It is difficult to imagine that neuronal and (poorly understood) glial mechanisms relevant to NS are limited to the handful of examples evoked above -which themselves pose challenges for therapeutic utilisation, such as the contrasting implication of dopamine (DA) D2 receptors in NS vs positive symptoms, and the widespread and heterogeneous role of glutamatergic transmission throughout the brain (Remington et al., 2011; Schobel et al., 2013; Poels et al., 2014) . Furthermore, it is not necessarily cellular processes implicated in the genesis of NS that are the key issue -they may be developmentally decoupled in time from treatment. Rather, it is those processes involved in the maintenance and counter-regulation of NS that best provide a potential foundation for improved pharmacotherapy. The optimal entrance point, as opposed to a susceptibility gene, would be a modulatory mechanism (facilitatory or inhibitory) upstream, downstream or in parallel to causal processes and still accessible to manipulation. As an analogy, and irrespective of whether 5-HT levels are genuinely deficient in major depression, SSRIs act by interfering with 5-HT reuptake, yet a dysfunction of 5-HT transporters is not incriminated in the aetiology of this disorder (Millan, 2006) .
Concerning neural structures circuits related to NS, again we have the problem of establishing their precise roles in the maintenance and modulation of NS and, over and above this, cerebral regions are not in themselves targets for pharmacotherapy. Drugs acts at molecules, not on Brodmann areas. Nonetheless, such insights are instructive in several ways. First, they provide potentially useful parameters for clinical development: either imaging biomarkers for NS and patient stratification, or surrogate measures of medication efficacy and target engagement during clinical trials. Second, in the context of drug discovery, they suggest which large-scale structures should best be modulated and raise the possibility of the back-translation of imaging and EEG findings into animal models for schizophrenia. EEG procedures are pretty well characterised and, though still challenging, progress is rapidly been made into structural (white and grey matter) imaging in rodents, as well as fMRI of neural activity -for example a default mode network has recently been described (Bertrand et al., 2010; Broberg et al., 2013; Chin et al., 2011; Dodero et al., 2013; Ellegood et al., 2013; Schobel et al., 2013) . This corresponds to the "MATRICS" mantra of identifying comparable and translatable behavioural, electrophysiological and other readouts across animals in order to facilitate drug discovery. Third, cortical neural circuits can be directly recruited for the relief of NS by stimulation strategies and, in a different fashion, by cognitive-behavioural/psycho-social modes of therapy likewise evoked below (Section 4.7).
4. Current and prospective therapy of negative symptoms: clinical investigations 4.1. Studies of potentially improved treatment of negative symptoms: general considerations
In view of their disabling nature and high prevalence, an especially important topic addressed in this volume is the current treatment of NS and prospects for improved control (Arango et al., 2013; . Miyamoto et al., 2012) . In this light, the article by Davis et al. (2014) surveys the effects of currently-available pharmacotherapy, and discusses ongoing clinical trials of potential new medication. The article considers several complementary facets of the actions of drugs for the management of NS including; methodological issues and trial design -for which a consensus is emerging as to how studies should best be performed (Marder and Kirkpatrick, 2014) ; efficacy against primary compared to secondary NS; and the actions of antipsychotics themselves, antidepressants and diverse other classes of agent.
In this respect, it is worth pointing out that: (1) many older monotherapy studies of antipsychotics were undertaken with positive rather than NS as the primary readout, and often in acute psychosis and (2) many recent studies of "novel" mechanisms of action were designed for restoring neurocognition in association with antipsychotics, with measures of NS essentially "tagged on", and the effects of the drugs alone not always examined (Arango et al., 2013; Davis et al., 2014; Hanson et al., 2010; Hartling et al., 2012; Miyamoto et al., 2012; Murphy et al., 2006; Zhang et al., 2013) . Neither of these designs is optimal to detect an impact of a drug (novel mechanism of action) against primary NS. Indeed, clinical studies focussing on the influence of monotherapy with innovative agents on primary NS are still rare, but should become more frequent with: proactive Federal Drug and European Medicines Agency support, improved rating scales (Section 2.1) and agreement on core criteria like the duration of trial (12 and 26 weeks for Phase II and III respectively), exclusion of comorbid depression, and prior clinical stability for around 4-6 months (Marder and Kirkpatrick, 2014) .
The overview below has a very mechanistic "flavour" in highlighting the actions of selected interventions in relation to their influence upon above-mentioned cerebral circuits and neurotransmitters implicated in the pathogenesis of NS, with a particular focus on: the PFC, dopaminergic transmission, N-Methyl-D-Aspartate (NMDA) receptors, GABAergic signalling, oxytocin and serotonin. The profiles of three instructive agents are highlighted in view of the attention that have attracted (and that they are still attracting), albeit for very different reasons: amisulpride, bitopertin and oxytocin. In addition, in light of the current inadequacies of pharmacotherapy, quite extensive consideration is devoted to "alternative" stimulation-based and cognitive-behavioural-psychosocial approaches which have yielded promising data and appear to act via the modulation of cortico-subcortical networks underlying NS.
4.2. Limited efficacy of established and recentlyintroduced antipsychotics for controlling NS 4.2.1. Neuroleptics and second generation (5-HT2A4D2) antipsychotics Despite their efficacy against positive symptoms in the majority of subjects, and mirroring their limited relief of impaired social cognition and neurocognitive deficits, NS are poorly controlled by currently-available medication such as haloperidol, and second-generation successors like olanzapine and risperidone (Table 2) (Citrome, 2013; Hartling et al., 2012; Leucht et al., 2013; Naber and Lambert, 2009; Zhang et al., 2013) . Further, induction of extrapyramidal symptoms at higher doses of neuroleptics risks the induction of secondary NS, though this happens only rarely these days (Remington et al., 2011) . It was comparisons to (highish doses of) haloperidol and other agents liable to provoke an extrapyramidal syndrome that initially implied the advantage of clozapine for alleviating NS, but more recent and longer-term investigations, studies in comparison to antipsychotics with a lesser propensity to induce NS, and observations in patients displaying predominant NS suggest that it is principally effective against secondary NS, and that its ostensible effectiveness against primary NS possibly reflects superior control of positive symptoms (Citrome, 2013; Davis et al., 2014; Hartling et al., 2012; Leucht et al., 2013) . For second-generation antipsychotics, there is only inconsistent evidence for advantages vs older agents in terms of efficacy against NS Hartling et al., 2012; Naber and Lambert, 2009; Zhang et al., 2013 ). This does not, at least in one sense, seem so surprising. Notwithstanding a potpourri of pharmacological activities, these agents are typified by their common and preferential 5-HT2A over D2 receptor antagonist profiles which, while diminishing the risk of an extrapyramidal syndrome -and perhaps effective for moderating hallucinations -would not, on a mechanistic basis, be anticipated to markedly reinforce the control of NS (Citrome, 2013; Meltzer, 2012; Miyamoto et al., 2012; Millan et al., 2000) .
A role for α2-adrenoceptor blockade in antipsychotic impact on NS
Some recently-introduced agents have been oriented towards the improved control of NS on the grounds of more relevant pharmacological properties. For example, blockade of α2-adrenoceptors reinforces frontocortical vs mesolimbic DA release and may, in theory, exert a beneficial influence upon certain sub-domains of NS (Brosda et al., 2014; Franberg et al., 2012; Millan et al., 2000 Millan et al., , 2012 . Asenapine shows high antagonist potency at α2-adrenoceptors compared to other second-generation agents (Franberg et al., 2012) , and also behaves as a 5-HT1A and 5-HT6 receptor antagonist which should favour cognitive performance (Loiseau et al., 2008; Meffre et al., 2012; Millan et al., 2012) . Indeed, reports of beneficial effects of sublingual asenapine against NS (Weber and McCormack, 2009; Citrome, 2013) are intriguing and over 52 -but not 26 -weeks it out-performed olanzapine. Nonetheless, it has not been authorised for control of NS and, unless underpinned by more robust findings, putative control of NS by asenapine seems unlikely to be of major relevance in a routine context (Arango et al., 2013; Buchanan et al., 2012; Citrome, 2013; Potkin et al., 2013) . Moreover, the contribution of α2-adrenergic receptor blockade to its actions remains to be elucidated and several other antipsychotics similarly elevate frontocortical release of DA by contrasting mechanisms: 5-HT1A partial agonism (ziprasidone) and 5-HT2C receptor blockade (olanzapine). As for clozapine, relative to modest D2 receptor blockade, it possesses all three of these actions and robustly increases dialysis levels of DA in the rodent PFC (Meltzer, 2012; Millan et al., 2000) . Thus, it is uncertain how the molecular signature of asenapine relates to any distinctive influence on NS, and to what extent increases in frontocortical release of DA may be related to its putative relief of NS (see Section 4.3 for a further consideration of the role of DA release in the PFC).
4.2.3. Case report: amisulpride and the potential significance of 5-HT7 receptor blockade The benzamide derivative, amisulpride, also warrants a brief digression for several reasons, some of them paradoxical. First, it is authorised for treating NS in several countries (including France, its homeland), despite the fact and the overall clinical picture for efficacy still remains rather nebulous. Early studies uniformly suggested improvement of NS, yet with ambivalent efficacy against positive symptoms, while other studies questioned its superiority to olanzapine and haloperidol at equi-effective doses vs positive symptoms (Leucht, 2004; Moller, 2003) . More recent work remains ambiguous concerning any putative and specific impact upon primary NS (Ahn et al., 2011; Leucht et al., 2013; Nuss and Tessier, 2010; Zhang et al. 2013) .
Second, reflecting its unusually poor blood brain barrier penetration, despite potent (low nM) affinity at D2/D3 receptors, amisulpride has a long onset of action and necessitates administration of very high doses of up to 500-1000 mg. It was proposed that doses at the lower end of this range (50-300) are most appropriate to controlling NS since they preferentially occupy extra-striatal D2 receptors whereas higher doses (400-1200) are more suitable for moderating positive symptoms in that they block striato-accumbus populations of D2 receptor (Bressan et al., 2003; La Fougère et al., 2005; Meisenzahl et al., 2008; Moller, 2003) . However, there is no obvious reason why the former mechanism should counter NS, proposed explanations of preferential D3 vs D2 receptor blockade and/or antagonism of pre vs postsynaptic D2 receptors have little real foundation, and amisulpride does indeed occupy striatal populations of D2 receptor at clinically-active doses (La Fougère et al., 2005; Meisenzahl et al., 2008) . Thus, the putative efficacy of amisulpride against NS would appear to require an alternative hypothesis.
Third, while amisulpride can be distinguished from the prototypical preferential 5-HT2A4D2 receptor profile of other second generation antipsychotics, recent studies have shown that it is not entirely "devoid of serotonergic actions" in that it possesses significant antagonist properties at 5-HT7 receptors. Though other agents like olanzapine also recognise these sites, their 5-HT7 actions are swamped by their additional receptor interactions at muscarinic receptors, histamine H1 receptors and α1-adrenoceptors etc. (Citrome, 2013) . By contrast, the more discrete antagonism of 5-HT7 receptors may be implicated in the actions of amisulpride in animal models related to NS (Abbas et al., 2009; Nikiforuk et al., 2013) . Moreover, antagonism of 5-HT7 receptors is associated with antidepressant properties in rodents (Hedlund, 2009) , which have also been reported for amisulpride (Abbas et al., 2009) . This is of particular relevance since its apparent relief of NS may be secondary to a reduction of depressed mood (Buchanan, 2007) .
Further evaluation of the significance of 5-HT7 receptor blockade to the control of NS may be warranted.
4.3. Antidepressants and reinforcement of frontocortical dopaminergic transmission: a role for 5-HT2C receptor inactivation?
As mentioned above, compromised activity of mesocortical dopaminergic pathways has been implicated in NS, though it cannot account for the full range of dysfunction. Essentially all classes of clinically-active antidepressant increase extracellular levels of DA in the FCX in freely-moving rodents via a variety of mechanisms, including (1) blockade of 5-HTC receptors and α2-adrenoceptors (mirtazepine) and (2) indirect recruitment of 5-HT1A autoreceptors (5-HT reuptake inhibitors like citalopram) (Alex and Pehek, 2007; Brosda et al., 2014; Meltzer, 2012; Millan, 2006) . The beneficial influence of antidepressants upon social anxiety via 5-HT2C receptor blockade or 5-HT2C receptor desensitization (uptake inhibitors) Millan, 2006) , and the possibility that relief of depressed mood may secondarily improve NS, has encouraged studies of the coadministration of antidepressants with antipsychotics (Hanson et al., 2010; Davis et al., 2014) .
In fact, the latter point remains the crux of the issue since, despite modest evidence that augmentation with antidepressants like mirtazapine and citalopram may be favourable in patients with prominent NS, effects are modest and it is uncertain whether NS are directly impacted or indirectly improved via alleviation of depressed mood (Arango et al., 2013; Davis et al., 2014; Kishi and Iwata, 2013; Rummel et al., 2006; Singh et al., 2010; Sommer et al., 2012) . It also remains unclear whether the potentiation of frontocortical DA release is fundamental to their actions, since most second generation antipsychotics likewise promote DA release in the PFC of rodents, despite inactivity against NS (Meltzer, 2012) . Another potential mechanism of antidepressant action would be strengthening of reward mechanisms by an as yet poorly-understood enhancement (not requiring DA release) of postsynaptic DA signalling in the nucleus accumbens -though it is unclear why this action would not exacerbate psychosis (Millan, 2006; Remington et al., 2011) . Adrenergic and serotonergic actions mediated independently of DA transmission and affecting reward, motivation and social behaviour may likewise be implicated in the actions of antidepressants (Millan, 2006) . These issues lie beyond the remit of this paper yet, irrespective of mechanistic and conceptual deliberations, an agent that both alleviates depressed affect and NS would be attractive to patients, so further study of the clinical impact and mechanisms of action of antidepressants against NS appears desirable (Chertkow et al., 2009; Kishi and Iwata, 2013) .
It is possible that induction of frontocortical DA release is related to the actions of other classes of adjunctive agent under evaluation in schizophrenia such as nicotinic α7 modulators, though greater interest has been ascribed to their putative improvement of cognition rather than NS (Jones et al., 2012; Millan et al., 2012) , an issue considered by Davis et al. (2014) in this volume.
These authors likewise discuss adjunctive use of the vigilance-promoting agent, modafinil, as well as the psychostimulants, methylphenidate and lis-dexamphetamine, for the treatment of NS inpatients stabilised on antipsychotics. However, their genuine efficacy at acceptable doses not risking exacerbation of psychosis remains an issue. In addition, it is unclear to what extent the increase in frontocortical DA and noradrenaline levels (related to enhanced attention) are involved in their putative actions compared to actions on limbic-striatal pools of DA (favouring motivation and reward Remington et al., 2011) ). Other mechanisms should not be excluded for modafinil, a particularly promiscuous agent (Millan, 2006; Scoriels et al. 2013) .
Overall, there are arguments that strengthening compromised mesocortical DA transmission in schizophrenia might favourably influence NS, but rigorous proof is lacking, no agent has yet been described that specifically recruits this mechanism to alleviate NS, and this is unlikely to be sufficient alone as exemplified by second-generation antipsychotics which enhance DA release in the PFC of rodents yet fail to robustly control NS. Note, moreover, that Phencyclidine (PCP) markedly accelerates the release of DA in the PFC of rodents (Millan et al., 1999 ), yet it is hardly an efficacious treatment for NS! Interestingly, there appears to be a bell-shaped relationship for DA release in the PFC and function either insufficient or excessive frontocortical dopaminergic transmission is deleterious to affect, cognition and behaviour, and hence might be linked to NS (Balla et al., 2012; Millan et al., 1999; Remington et al., 2011) .
Finally, it is possible that mechanisms independent of monoamines are involved in the actions of antidepressants, such as interactions with sigma1 receptors and ion channels (Millan, 2006) or, as recently proposed, modulation of GABAA receptor-mediated signalling (Silver et al., 2011) .
Anxiolytics and positive modulation of GABAA receptors
As recently reviewed elsewhere (Dold et al., 2013) , though possibly useful for short term control of agitation and aggression , there is little evidence for the utility of adjunctive benzodiazepines in the management of NS. Despite the not unreasonable argument that relief of social anxiety might secondarily diminish NS, this remains to be demonstrated. Benzodiazepines act as positive allosteric modulators (PAMs) at GABAA receptors, which retain their interest in light of the functional downregulation of frontocortical chandelier GABAergic interneurones in schizophrenia. More specifically, loss of GABAα2 subunit on pyramidal neurone axon initial segments may contribute to the desynchronisation of frontocorticosubcortical glutamatergic circuits (Hines et al., 2013; Lewis, 2012; Stan and Lewis, 2012) . Interestingly, a recent fMRI study related alterations in GABAA signalling in the PFC to the modulation of affect, and actions of lorazepam were more pronounced in schizophrenic patients, perhaps reflecting loss of GABAergic inhibition and GABAA receptor supersensitivity (Taylor et al., 2014) . While the GABAAα2 agonist, MK 0777, exerted little benefit on cognitive symptoms in association with antipsychotics (Buchanan et al., 2011a) , it would be interesting to evaluate its actions as monotherapy in patients with predominant NS, and as early as possible in the disorder (Lewis, 2012; Millan et al., 2012) .
Interest in GABAA receptor modulation is supported by observations with the neurosteroid, pregnenolone, of which the metabolite allopregnenolone behaves as a PAM at GABAA receptors. Both experimental and clinical data suggest that adjunctive pregnenolone alleviates NS (and possibly cognitive symptoms). While its precise mechanism of action awaits clarification and clinical data require consolidation, this would appear a promising piste for further study Ritsner et al., 2010 Ritsner et al., , 2014 Marx et al., 2011) supported by studies in animals (Wong et al., 2012) .
Correcting anomalous glutamatergic transmission: metabotropic and ionotropic (NMDA) receptors
4.5.1. Positive modulation of Glycine B sites on NMDA receptors In fact, there is evidence that pregnanolone itself potentiates transmission at NMDA receptors (Marx et al., 2011) . This is of relevance since one well-established hypothesis in schizophrenia is that a hypoactivity of frontocortical NMDA receptors results in reduced activity of chandelier GABAergic interneurons, leading in turn to the above-mentioned disorganisation of neural networks linking cortical and subcortical structures (Coyle et al., 2012; Gilmour et al., 2012; Millan, 2005; Stan and Lewis, 2012) . Accordingly, one argument underlying the development of metabotropic glutamate 2/3 partial agonists/PAMs for schizophrenia was that, by virtue of their actions at metabotropic glutamate 2 autoreceptors on glutamatergic neurones, they would "normalise" the activity of disinhibited glutatamatergic pathways, as shown by their blunting of PCP-induced glutamate release in the FCX of rats. Nevertheless, despite promising initial data for both NS and positive symptoms, further clinical studies proved inconclusive Stauffer et al., 2013) .
A direct approach to restituting the activity of NMDA receptors surmised to be deficient in schizophrenia is to recruit their positive, modulatory Glycine B site (De Bartolomeis et al., 2012; Hashimoto et al., 2013; Javitt, 2012; Millan, 2005) . Though no Glycine B drug has ever been tested alone, an extensive series of small scale and larger, controlled multi-centre clinical studies has been undertaken with: (1) the endogenous agonists, Glycine and D-Serine, (2) the synthetic partial agonist, D-Cycloserine and (3) the endogenous inhibitor of glycine reuptake, sarcosine, in association with antipsychotics other than clozapine -which itself reinforces NMDA transmission, thereby compromising study outcome (Millan, 2005) . Briefly summarised, these studies have yielded a chequered pattern of data permitting no definitive conclusions (nor, of course, drug authorisations) yet with the most promising suggestion of efficacy -somewhat counter-intuitively -for NS rather than for cognitive or positive symptoms, and with greater activity associated with full rather than partial agonism, exerted either directly or via suppression of glycine reuptake (Buchanan, 2007; De Bartolomeis et al., 2012; Gilmour et al., 2012; Javitt, 2012; Kantrowitz and Javitt, 2010; Lane et al., 2010; Singh and Singh, 2011; Weiser et al., 2012) .
Case report: the Glycine 1 transporter inhibitor, bitopertin -hot off the press
These clinical observations and the above-evoked notion that NMDA receptor hypoactivity may be pivotal to the aetiology of schizophrenia, prompted the development of bitopertin, a highly selective ligand at Glycine 1 transporters, which are localised in the vicinity of neurones bearing NMDA receptors in the PFC and other cerebral regions (Alberati et al., 2012) . Guided by PET studies of target engagement, a double-blind, placebo-controlled, 8 week randomised study of subjects with predominantly NS revealed significant effects of 10 and 30 mg in the NS factor score of the PANSS and in Clinical Global Improvement, whereas a higher dose of 60 (mirroring the "inverted U" dose-response of direct ligands (De Bartolomeis et al., 2012)) did not separate from placebo (Umbricht et al., 2010) .
The promising -though not overwhelming -Phase II data, coupled to an excellent safety profile, encouraged the decision to simultaneously launch three Phase III add-on trials in patients with persistent and predominant NS. Three further and large add-on trials with doses of 5-20 mg of bitoperin were also initiated in patients with suboptimal control of all symptoms, likewise over 52 weeks, and in the same centres. The primary endpoint of the three NS trials was the PANSS at 24 weeks.
Frustratingly, Roche have just revealed that the initial outcome of the bitopertin studies for persistent and predominant NS was negative. No other details nor analyses are as yet available, but it is important to consider why these studies may not have succeeded overall in view of: their considerable interest; the inevitable fall-out; and potential insights into putatively responsive patient sub-groups and related therapeutic strategies.
From FCX pools of Glycine to D-Serine for improved control of NS
It may be that use of newer NS metrics mentioned above (Section 2.) would have been more successful -and sensitive -and a focus on NS sub-clusters might also have been more insightful. As regards mechanistic explanations, stressinduced glutamate release in hippocampus is implicated in the induction of psychotic states, so actions at NMDA receptors in this region may be deleterious (Schobel et al., 2013) . In addition, we have little idea of how facilitating NMDA activity in other subcortical structures implicated in the genesis and putative control of NS, like the dorsal striatum, nucleus accumbens and amygdala, may affect their expression. A further issue is the preferential localisation of Glycine 1 transporters in hindbrain vs forebrain stuctures, where they more markedly elevate extracellular levels of glycine than in the PFC itself (Gobert et al., 2011 and pers.comm.) . Perhaps most fundamentally, however, following initiation of the bitopertin studies, evidence emerged that D-Serine rather than glycine may be the principle endogenous ligand gating NMDA receptors controlling synaptic plasticity in PFC (Papouin et al., 2012; Fossat et al., 2012) . Though such observations are most obviously related to the control of cognition, they are ultimately also germane to NS.
Thus, apart from the all too familiar message that a positive Phase II outcome is no guarantee of Phase III success, there may be something of a silver lining. Rather than fruitlessly searching for other ligands that putatively increase levels of endogenous Glycine at NMDA receptors in PFC, greater success may be acquired with strategies that preferentially elevate extracellular levels of D-Serine. A "bitopertin-mimic" strategy aimed at increasing ambient levels of D-Serine will depend upon further characterisation of the transporters clearing D-Serine from the synaptic cleft Millan, 2005; Sacchi et al., 2013) . Alternatively, D-Serine signalling may be strengthened by inhibition of the degrading enzyme, D-Amino-acid-Oxidase (Ferraris and Tsukamoto, 2011) . Indeed, very recently, the D-Amino-acid-Oxidase inhibitor, benzoate, was found to be effective in both PANSS total and NS sub-scale scores in a 6 week, double-blind, placebo-controlled add-on trial of chronic schizophrenia . Clearly, confirmation of these encouraging data in more extensive trials of longer duration, and employing more selective inhibitors, would be desirable.
A further strategy would be to inhibit the synthesis of kynenurenic acid, an endogenous antagonist of the Glycine B sites which likewise behaves as an antagonist of nicotinic α7 receptors, suggesting a double therapeutic advantage for controlling NS -and neurocognitive impairment (Alexander et al., 2012; Jones et al., 2012; Schwarcz et al., 2012 ).
Recruitment of cortical networks by stimulation techniques
The traditional notion of hypofrontality per se as a causal factor underlying NS and other non-positive facets of schizophrenia has been superseded by a more sophisticated and refined model of state, sub-territory and timedependent dysfunction expressed in interaction with cortical and sub-cortical networks (Section 3.2). Anomalous operation of the PFC, including hypoactive NMDA receptors, down-regulated GABAergic interneurones, desynchronised pyramidal neurones and blunted DA release are nonetheless implicated in the pathophysiology of schizophrenia, including NS (see above). Not least owing to the long kinetics of new drug development, and limited progress to date with new classes of agents, there is increasing interest in other strategies for modulating the action of the PFC and further cortical regions to therapeutic ends.
High frequency (410 Hz) rTMS of the PFC, in particular the DLPFC, enhances brain metabolism and excitability. It has been reported (in several though not all studies) to be effective in the relief of NS when applied for several weeks early in the course of schizophrenia, with an impact on several subdomains of NS (except alogia), and independent of any change in depressive symptoms (Barr et al., 2012; Shi et al., 2014) . Interestingly, there is some evidence that its actions involve modulation of NDMA receptors and striatal DA release, possibly to favour motivation (Pell et al., 2011; Stratella et al., 2001) .
Transcranial, direct current stimulation involves the application of a weak electric current via two electrodes to increase neuronal excitation in the underlying regions of the brain. Despite some conflicting observations, it holds promise for the monotherapy of major depression (Berlim et al., 2013) , can promote social cognition (when applied over the temporo-parietal junction) (Santiesteban et al., 2012) , and is currently under study for the treatment of NS (and auditory hallucinations) of schizophrenia. Electrodes are placed over the left DLPFC (anode) and temporopartietal junction (cathode), and recruitment of corticosubcortical networks appear to be involved in its beneficial impact on NS, though this awaits confirmation and the effects of direct current stimulation depend, like those of rTMS, upon the precise parameters of stimulation employed (Agarwal et al., 2013; Brunelin et al., 2012) .
Ongoing studies should help standardise stimulation parameters and clarify the genuine utility of these approaches for recruitment of frontocortical mechanisms and the alleviation of NS.
Cognitive and psychosocial interventions for relieving NS: implication of frontocortical circuits
A different approach to restore the functionality of corticosubcortical circuits disrupted in schizophrenia consists in the application of interrelated -and sometimes combined -"cognitive-behavioural-psychosocial" therapies. A diverse palette has been described, certain of which are proposed for the treatment of NS and/or impaired neurocognition and deficits in social cognition. They are undertaken either individually or as group therapy, and almost invariably on top of antipsychotic medication to guarantee robust control of positive symptoms (Barsaglini et al., 2014; Elis et al., 2013; Johnson et al., 2013; Valencia et al., 2013) .
The behavioural training (practise) technique of Cognitive Remediation Therapy (CRT) aims to endurably rekindle key skills related to neurocognition and social cognition, and has been shown to recruit a distributed network of frontocortical structures including the inferior frontal gyrus, DLPFC and anterior cingulate cortex, all implicated in NS (Section 3.2) (Bor et al., 2011; Haut et al., 2010; Wykes et al., 2011) . The (modest) amelioration of NS by tailored programmes of CRT includes an decrease in avolition and may be related to an enhancement of motivation (Elis et al., 2013; Klingberg et al., 2012; Sanchez et al., 2014; Wykes et al., 2011) . Though enhanced executive function may help improve patient outcome following CRT, its contribution remains unclear.
A rather different approach is represented by Cognitive Behavioural (or simply Cognitive) Therapy (CBT) -the first "alternative" mode of therapy to be formally endorsed by national organisations both in the UK and US (Buchanan et al., 2010; Dixon et al., 2010 , Jauhar et al., 2014 . This technique more specifically targets poor motivation and anhedonia together with negative and defeatist beliefs, and promotes the active engagement of patients to attain defined goals: it can be oriented to an individual's strengths and has as a core objective improved functional status and, if possible, recovery Grant et al., 2012) . Several papers have reported a positive though moderate impact of CBT on NS (mainly in association with antipsychotics), with a reduction of apathy and enhanced motivation, including studies in patients with predominant NS. Benefits depend upon the conditions of application, individual sessions are more effective than group therapy, not all studies have been successful and overall effect size is modest for NS -and positive symptoms (Elis et al., 2013; Jauhar et al., 2014; Morrison et al., 2014) . Also, just how specific and marked the impact of CBT on NS is compared with CRT remains to be clarified (Klingberg et al., 2012) . Nonetheless, in light of evidence for enduring post-treatment efficacy in major depression, where it has been more extensively studied, it is interesting that effects may persist after discontinuation in schizophrenia -though this observation should not be conflated with any notion of a permanent cure (Cuijpers et al., 2013; Elis et al., 2013; Grant et al., 2012; Hollon et al., 2006; Sarin et al., 2011) . Underpinning the significance of higher level operations in the mediation of CBT, there is evidence for a role of functional changes in the striatum and other cerebral regions like the insular cortex in transducing its effects on emotional processing, though the relationship of such changes to NS awaits clarification (Kumari et al., 2011) .
A final and complementary intervention worth highlighting here is Social Skills Training which aims to moderate NS by the use of intensive and structured modules that educate patients about skills needed to improve their social function in the community, including reciprocal use of verbal and nonverbal exchanges. A reinforcement of social cognition is evidently an important element of this approach for countering NS, underscoring arguments made above concerning their close interrelationship and underpinning the notion that NS lie at least partially downstream of social cognition/processing (Section 2.3) (Figure 4) (Elis et al., 2013; Valencia et al., 2013) . Evidence is accumulating to suggest the utility of group Social Skills Training for relief of NS (Elis et al., 2013; Rus-Calafell et al., 2013) . Interestingly, coupled to family psychoeducation, Social Skills Training was a lynchpin of the broad-based early-intervention "OPUS" programme in Denmark which reported positive findings for the improvement of NS in individuals with firstepisode psychosis (Hastrup et al., 2013; Nordentoft et al., 2014) .
As for CRT and CBT, standardisation is an issue with Social Skills Training, and it remains to be determined just how general, robust, broadly-applicable and cost/time-effective each of these interventions would be when used on a larger scale outside the framework of controlled and specialistcoordinated trials, but cautious optimism seems warranted (Jauhar et al., 2014) . Further, by analogy to the uniting of pharmacotherapy and non-drug based strategies, combining cognitive-behavioural-psychosocial therapies could potentially boost efficacy, as reflected by Integrated Psychological Therapy, though no rigorous comparative data are yet available (Elis et al., 2013; Roder et al., 2011) . Intriguingly, "cognitive-behavioural-psychosocial" therapies appears to improve the real-world function of patients, and vocational reintegration itself moderates NS, implying a sort of "positive feedback" (Bio and Gattaz, 2011) .
As a final remark, while the focus above was on the PFC, certain alternative therapies like Social Skills Training likely facilitate social communication and motivation by promoting oxytocin release, itself deficient in NS. Yoga has been claimed as useful for treating NS and, notwithstanding any reservations concerning the rigour of the underlying studies, yoga therapy aimed at improving socio-occupational function was reported to increase plasma oxytocin levels (Jayaram et al., 2013) . Thus, we may conclude this overview of potential routes to superior therapy of NS with a brief consideration of the use of this hormone itself.
Oxytocin: countering NS via reinforcement of social cognition/processing
As pointed out above (Section 2.3), the interface between NS and impaired social cognition-processing is somewhat blurred with several communalities in terms of their expression, underlying causes and neural substrates. It might be argued that certain domains of NS lie at least partially downstream of -and are driven by -impairments in social cognition as regards both of its components, emotional processing and Theory of Mind. Hence, reinforcing social cognitive should have a beneficial influence upon NS. While the pharmacology of social cognition is not well developed, based on both experimental and clinical work, at least one critical modulator has been identified, oxytocin. This neuropeptide possesses its own class of centrally localised oxytocin receptor, and interacts with a variety of neuromodulators in the expression of its actions, including 5-HT and DA in the nucleus accumbens and amygdala, respectively (Goodson and Thompson, 2010; MeyerLindenberg et al., 2011; Millan and Bales, 2013; Millan et al., 2012; Rosenfeld et al., 2011) .
As discussed elsewhere, though its long-term actions appears to be rather more complex and less unitary than originally thought (De Berardis et al., 2013; Huang et al., 2014; Modabbernia et al., 2013) , oxytocin is a powerful facilitator of social cognition under a diversity of conditions. By analogy to autism, intra-nasal administration of oxytocin favours at least some components of social cognition in schizophrenia, notably Theory of Mind and emotion recognition De Berardis et al., 2013; FischerShoffy et al., 2013; Millan et al., 2012) . Further, certain studies suggest a beneficial impact of adjunctive, long term (several weeks) -but not single dose ) -administration of intranasal oxytocin on NS in patients stabilized on antipsychotics (Feifel et al., 2010 ; P.R. Modabbernia et al., 2013; Pedersen et al., 2011) . These studies require consolidation and it is unclear: exactly which populations of patients are most likely to respond; in what context (possibly social enrichment); and as concerns which dimensions of NS -though avolition and anhedonia have been proposed (P.R. . It also remains to be established via which neuronal substrates oxytocin exerts its actions. Animal studies suggest a role for: (1) the nucleus accumbens in interaction with reward mechanisms and 5-HT (Dolen et al., 2013) and (2) the amygdala-PFC in interaction with dopamine and emotional processing (Rosenfeld et al., 2011) , though these networks are likely interrelated. Oxytocin may also counter NS by promoting social motivation (Gordon et al., 2011) , or via a more strictly social cognitive mechanism such as an enhancement of Theory of Mind (Section 3.6) (Churchland and Winkielman, 2012; Davis et al., 2013; Millan et al., 2012; Pedersen et al., 2011) .
To echo a comment made above, irrespective of mechanistic niceties, a dual improvement in social cognition and NS would be particularly appealing for restoring function both in schizophrenic subjects and in at-risk individuals prior to diagnosis. This promising avenue of research will hopefully soon be consolidated and accelerated by the clinical availability of non-peptidergic PAMs at oxytocin receptors (Ring, 2010) .
Prospects for improved clinical evaluation and treatment of NS
As evoked above, a common feature of pharmacotherapeutic, stimulation and cognitive-behavioural-psychosocial techniques for countering NS is their recruitment of mechanisms integrated in cortico-subcortical circuits, especially those involving the PFC. However, the precise neurochemical pathways engaged remain to be further clarified and they presumably differ amongst various clinical strategies, each of which acts via a multiplicity of neural substrates.
It should also be stressed that, despite encouraging results, no medication or alternative approach under investigation promises to become a panacea in terms of universal and robust efficacy, cost effectiveness, ease of application, use as monotherapy and long-term control of NS together with other classes of symptom. Despite all this, there are grounds for guarded optimism.
First, from a methological perspective, there is an emerging consensus as to how focussed clinical trials should be optimised for revealing a potentially beneficial influence of a novel candidate drug against primary NS: inclusion criteria, length of treatment and many other variables are becoming increasingly well defined to favour the likelihood of a successful outcome (Marder and Kirkpatrick, 2014) . In addition, the European Medicine and Federal Drug Agencies appear increasingly open to dialogue concerning innovative trial designs and novel concepts for treating NS and other unmet needs in schizophrenia. Furthermore, several novel rating scales under exploration appear to be more reliable and sensitive than conventional tools for monitoring the benefits of therapy (Section 2.1) (Malaspina et al., 2014; Marder and Kirkpatrick, 2014) . Within this framework, it should soon become possible to differentiate the impact of novel agents upon distinctive NS sub-domains like diminished emotioanal expression vs avolition which will not necessarily be modulated in parallel, in line with their distinct pathophysiological substrates (Section 3).
Second, trial failures can be demoralising when hopes were high and studies well-designed and well-conducted, as exemplified by bitopertin. However, rigorous analysis of full clinical data sets may reveal hidden beneficial actions, for example on sub-domains of NS or in specific subpopulations -and even permit re-purposing towards alternative pathologies. Additional clinical and experimental exploration of the "NMDA/glycine" hypothesis may reorient "R and D" in a more promising direction -in the case of bitopertin, one might argue, from glycine towards D-Serine based therapies (Section 4.5). Mirroring a plethora of recent trials of potential pro-cognitive agents, bitopertin was tested in association with conventional antipsychotics but they may well interfere with any benefical influence on impaired neurocognition, NS and deficits in social cognition (Section 2.1) . Two non-exclusive solutions may be evoked. (1) Integrate a novel and promising mechanism of action into a multi-target profile incorporating several complementary pharmacological properties to underpin efficacy against NS and likewise control other classes of symptom. (2) Should a new agent (mono or multitarget) not be suited to the control of positive symptoms, the drug concerned can be tested either in patients presenting with persistent NS or during the prodrome: in the latter instance, it would relieve the distress of prominent NS and potentially reduce transition to frank psychosis (Fusar-Poli et al., 2013a; Sabbag et al., 2011) .
Third, as indicated above, pharmacotherapy is not the only avenue towards improved therapy for NS: alternative strategies warrant systematic evaluation from cortical stimulation, to a suite of "cognitive-behavioural-psychosocial" interventions exploited alone and/or in "packages" (Elis et al., 2013) . As argued elsewhere for other classes of symptom -and disorder (Chou et al., 2012; Millan, 2006 Valencia et al., 2013) -it may prove more productive to consider the association of a new pharmacological mechanism of action with a non-pharmacotherapeutic strategy for optimal expression of advantages, rather than persisting in adjunctive use with conventional antipsychotics. Whether this goal is attainable in the course of initial clinical development remains to be seen but, as indicated above, imaginative trial design together with support from regulatory agencies could eventually make such studies, like drug evaluation in the prodrome, a realistic proposition.
Finally, improved knowledge of the pathogenesis of NS in terms of the cerebral circuits involved and their molecular underpinnings will hopefully reveal novel targets for improved pharmacotherapy (Table 2 ). In addition to increasingly refined studies in patients, success will depend upon the progressive improvement of animal models, as outlined in the following section.
5. Experimental studies of negative symptoms: readouts and animal models
Animal models for studying NS: general considerations
As intimated in the previous section, an important issue addressed in this Special Volume is the use of experimental paradigms for modelling NS, for elucidating their pathophysiological substrates, and for the identification and validation of novel agents for their alleviation (Figure 6 ). It would be naïve to imagine that one could fully reproduce NS and the uniquely human condition of schizophrenia in an animal. Accordingly, we are concerned with models for rather than of NS and schizophrenia, and in each case designed to shed light on specific underlying mechanisms and symptoms -it is unlikely than any hypothetical "one-stop" paradigm will be found. In this light, apart from core considerations of model reliability and reproducibility, it is useful to keep in mind the familiar criteria of: (1) face value (models for NS should at least partially mirror observations in human patients); (2) construct value (they should reproduce or mimic at least certain pathophysiological (neural and neurochemical) mechanisms underpinning NS) and (3) predictive value (the influence of pharmacotherapy on measures for NS should correlate with and anticipate clinical activity in patients). The latter goal is the most challenging of all for essentially any animal model, but particularly so for NS since no robustly-active therapeutic agent is known (Section 4). As sketched out below and analysed in this Special Volume, fulfilling the other two criteria is likewise anything but straightforward (Der-Avakian and Markou, 2012; Gururajan et al., 2010; Pratt et al., 2012; Trezza et al., 2011a Trezza et al., , 2011b .
The two interrelated and cores themes are. First, readouts relevant to NS, of which the most accessible in rodents are social behaviour -as discussed by Wilson and Koenig (2014) -and motivation/reward-driven behaviour -as considered by Barnes et al. (2014) . Second, animal models for the induction of NS-like behaviours provoked by pharmacological (Neill et al., 2014) , developmental (O'Tuathaigh et al., 2014) and genetic (Moser, 2014) manipulations. The following paragraphs: underscore the major messages of these papers, present several procedures outside their scope, highlight some new and insightful observations, discuss prospects for improved experimental study of NS and -a little provocatively -ask whether the endless hand-wringing over the ostensibly unique difficulties faced in setting up models and readouts of NS in animals is genuinely legitimate compared to other cardinal symptoms of schizophrenia.
Models for NS compared to cognitive and positive symptoms in rodents: a unique challenge?
As mentioned above, it is bemoaned -or at least intrinsically assumed -that modelling NS of schizophrenia is inherently more complicated than other dimensions of the disorder. However, it is worth reflecting as to whether this genuinely the case, in particular in comparing NS to positive symptoms.
Procedures for interrogating neurocognitive domains like attention, working memory and executive function are fairly well-established in rodents -with several translatable to humans and their disruption can be studied in a variety of experimental models for schizophrenia, despite the continuing challenge of social cognition (Buchanan et al., 2011b; Millan and Bales, 2013) .
As regards positive symptoms, the tacit assumption is that animal models are pretty undemanding. However, this seems based on the unspoken notion that easy to treat in patients must mean easy to model in animals. Yet, as regards "face value", delusional thinking and paranoia seem quite a long way removed from motor readouts like climbing behaviour (apomorphine), avoidance responses (conditioned) and hyperactivity (psychostimulant-induced) in rats, while recording head twitches in mice likewise seems a far cry from auditory hallucinations in patients (Castagné et al., 2009) . These empirical measures reflect activation of D2 and 5-HT2A receptors, respectively, paralleling the antagonist properties of currently-used second generation antipsychotics at D2 and 5-HT2A receptors (Section 4.1) (Meltzer, 2012) . On the other hand, other mechanisms involved in the induction of positive symptoms like disruption of GABAergic and glutamatergic transmission in FCX are not integrated into these models. This is a critical point since refractory patients may have a more "glutamatergic" than dopaminergic pathology and it is the resistance to treatment of positive symptoms in up to 30% of patients that is the genuine problem today: this notion of construct validity is poorly integrated into current models (Gilmour et al., 2012; Hashimoto et al., 2013; Javitt, 2012; Leucht et al., 2013; Poels et al., 2014) . Though NMDA antagonists are widely used for characterisation of drug actions against Figure 6 The diversity of experimental models and readouts available for experimental study of various sub-domains of NS. While procedures for studying asociality and amotivation are fairly well-established, blunted affect is far less accessible -few specific readouts have been proposed, and alogia may be inaccessible. In most published accounts, only one or two readouts have been employed and a single model for schizophrenia, with little effort to interlink behavioural observations to potential neural substrates. Hence, considerable work remains to be undertaken to improve the experimental study of the causes and modulation of NS, and there are many promising opportunities for progress. Abbreviations not in text: OE, overexpression; KO, knockout, KD, Knockdown (hypomorphic mice); R; Receptor; V Hipp, Ventral hippocampus; I:C, Inosine:Cytosine; Soc, Social; and PR, Progressive ratio.
positive symptoms -as well as NS (Neill et al., 2014 ) -they likewise have serious limitations (Javitt, 2012; Millan et al., 1999; Pratt et al., 2012) and animal models for DAindependent and refractory positive symptoms do not appear to be even on the horizon.
Thus, we may be naive in considering models of positive symptoms as unproblematic: other than predictively for detecting D2 receptor blockade, they are well off the radar as regards the current therapeutic need to find agents of greater efficacy in resistant patients. In addition, run of the mill models have tended to foster a mono-dimensional DAcentric approach to treatment of positive symptoms and drug screening for the best part of 50 years. Putative models for positive symptoms irresponsive to D2 (and 5-HT2A) antagonists may be the way to go if we wish to ameliorate treatment of positive symptoms. Yet it is precisely the criteria of good responsiveness to clinical-used agents that paradoxically may be impeding progress in the development of procedures for studying "resistance". Lack of effect of a clinically-used agent tends to downgrade the model and render claims of positive actions of drugs with novel mechanisms of actions suspect -at least in the eyes of those making key decisions for drug development. Something of a Catch 22, since if the drug does actually work in a conventional model it risks being unoriginal and lacking in inherent advantages over existing agents.
Readouts of NS-like behaviours in rodents
As for putative models for NS, the situation is radically different: "validation" by agents robustly active in the clinic is unfeasible -there simply are not any. Proof of irresponsiveness to haloperidol and other currently-used antipsychotics is simple to show, yet hardly convincing as an alternative strategy. While a modest response to clozapine, amisulpride, glycine reuptake inhibitors or oxytocin might be considered as encouraging (Section 4), there are no persuasive means of therapeuticallyrelevant, pharmacological validation. The predictive status of animal work on NS is then, unfortunately, nebulous, and will remain so until we finally find medication that is consistently effective against NS in patients. On the other hand, there seems no reason not to promote the construct validity of models and readouts by back-translating from human work (Section 3) and evaluating the status of, for example, frontocortical-temporal and cortico-striatal networks; GABA-glutamate coupling; DA release, and oxytocinergic transmission. This would necessitate an overdue mechanistic expansion of readouts from the behavioural measures classically used today (Figure 6 ). For example, how do alterations in social motivation and behaviour relate to oxytocin release and to electrophysiological measures of changes in fronto-temporal network activity, and how do alterations in effort invested to gain a reward relate to changes in the striatal release of cannabinoids and altered fronto-striatal circuit function (see further below, Section 5.8).
On the other hand, concerning face value, the status of animal studies of NS may not be as disastrous as one might think, despite the fact that our knowledge of their aetiology is limited (Section 3). Most obviously, asociality is accessible via direct measurement of active social interaction (Gururajan et al., 2010; Trezza et al., 2011a Trezza et al., , 2011b ) which can be modified by a variety of manipulations from the propsychotic agent, PCP (Neill et al., 2014) , to developmental (Moser, 2014) and genetic (O'Tuathaigh et al., 2014) models. As discussed in these papers, and in the keystone article of Wilson and Koenig (2014) , it is crucial to control for the influence of diverse factors that are not an intrinsic component of the asociality of NS, like attention, motor performance, sensory status, aggression and fear. The same holds for studies of mice in which the widely used 3-chamber test of social preference-sociability-social affiliation has been undertaken (Silverman et al., 2010; Millan and Bales, 2013) . In all procedures, as accentuated above, it is important to control for the intertwined factor of social cognition (Millan and Bales, 2013) . In any event, from the perspective of face value, social behaviour in rodents clearly does provide a framework for examining the perturbation and restoration of a core facet of NS, asociality.
As regards the hedonic state of consummatory pleasure (liking), this is only modestly compromised in schizophrenia whereas the anticipation of reward (wanting) and the initiation of behaviours to acquire it are strongly impacted (Foussias et al., 2014) . Measures of each of these dimensions of reward -and of the underpinning cognitive operations -have been well-studied in rodents, including social reward (Trezza et al., 2011a (Trezza et al., , 2011b , as discussed by Barnes et al. (2014) .
To summarise, the study of NS is certainly not simple, blunted affect still represents something of a conundrum and alogia (strictu sensu) may be intransigent to investigation in rodents. Nevertheless, there are sufficient experimental handles for progress to be made, especially as regards the sub-domains of asociality and amotivation (Section 5.8). The principle handicap remains the lack of an agent clinically effective against NS for test validation.
Induction of NS-like behaviours in diverse models for schizophrenia
Historically speaking, there has been a shift from pharmacological (psychostimulants, hallucinogens, NMDA antagonists etc.) to neurodevelopmental to genetic models for schizophrenia, with a recent tendency to reassert the primacy of developmental models and, ideally, to superimpose them on a genetic background (Section 5.8.3). Some environmental manipulations, like prenatal stress or perinatal inflammation, are not specific for modelling schizophrenia vs other psychiatric disorders -depression and autism, respectively (Fatemi and Folsom, 2009; Meyer and Feldon, 2010; Millan, 2013) . Further, certain risk genes like Disrupted in Schizophrenia-1 and Neuregulin-1 are associated with other disorders -bipolar disorder and autism, respectively (Meyer and Feldon, 2010; Millan et al., 2012; Pratt et al., 2012; Sullivan et al., 2012) . This should be borne in mind in interpreting the significance of NS-like symptoms. It should also be stressed that developmental, genetic and pharmacological models usually aim to mimic a risk factor posited to increase susceptibility for -or even provoke -schizophrenia, rather than just NS per se. In this sense, it might be argued that there are no genuine animal models for NS as such. Rather, NSlike behaviours and responses are examined in parallel with other symptoms and, over the past decade or so, the emphasis has been on a positive-like phenotype and neurocognitive disruption with only secondary attention devoted to NS -and social cognition Pratt et al., 2012) . This has somewhat biased the literature and even studies of social interaction (examined fairly routinely) have often not been sufficiently rigorous in dissecting out components directly related to NS, a limitation articulated by Wilson and Koenig (2014) , Moser (2014), and O'Tuathaigh et al. (2014) in this volume.
Accordingly, despite a revival of interest in NS, the literature is still fairly meagre as concerns their characterisation in animal models for schizophrenia. Further, very few studies have shown that NS-like observations can be normalised by pharmacological treatment, and even fewer have examined the actions of agents other than antipsychotics.
5.5. Social interaction and other measures of social behaviour 5.5.1. Pharmacological procedures Under conditions minimising anxiety, active and nonaggressive social interaction is fairly straightforward to record in rats, and it is consistently disrupted by acute and sub-chronic administration treatment of NMDA receptor open channel blockers like PCP and ketamine, with the effects of long-term exposure sometimes outlasting administration schedules (Gururajan et al., 2010; Koros et al., 2007; Neill et al., 2010 Neill et al., , 2014 Sams-Dodd, 1995; Wilson and Koenig, 2014) . This disruption of social interaction has frequently been termed "social withdrawal", though it is not obvious that any active process of "withdrawal" per se is actually taking place, and it is difficult to assert with confidence that diminished social motivation or reward is involved. Nonetheless, effects of NMDA receptor antagonists appear to be specific and, in view of their ability to induce NS in humans, it is not unreasonable to consider this procedure as relevant to the asociality of schizophrenia (Gururajan et al., 2010; Javitt, 2012; Neill et al., 2014) . Interestingly, and mirroring their clinical profiles in patients, haloperidol does not prevent perturbation of social interaction by PCP while clozapine and second generation antipsychotics exert inconsistent effects (Gururajan et al., 2010; Neill et al., 2014; Wilson and Koenig, 2014) . Curiously, amisulpride does not appear to have been examined and, irrespective of ambivalent clinical findings, the glycine reuptake inhibitor, bitopertin, would be of interest to examine. Conversely, there is evidence that 5-HT1A agonists counter impairment of social interaction by NMDA receptor antagonists (Boulay et al., 2004) and Cholecystokinin receptor 2 antagonists are likewise effective -since benzodiazepines were inactive, their mutual anxiolytic properties are presumably not relevant (Seillier et al., 2013) . Of special interest, oxytocin reverses the suppression of social interaction by PCP via an action in the amygdala, one putative site of action for enhancement of social behaviour: the actions of oxytocin are mimicked by vasopressin which, in a context-dependent manner, also expresses pro-social properties (Goodson and Thompson, 2010; Katayama et al., 2009; Lee et al., 2005; Matsuoka et al., 2005) .
It may be remarked that antagonists at mGluR5 receptors, which are functionally coupled to NMDA receptors (Millan, 2005) , likewise reduce social interaction in rats though this potential model has not apparently been exploited for the characterisation of mechanisms related to NS (Koros et al., 2007) .
As regards other mechanisms known to control social behaviour (and reward) and relevant to NS, cannabinoids are of particular interest in view of their effects in humans, and since PCP decreases social interaction at least partially by modulating endocannabinoid transmission in the PFCand probably amygdala (Seillier et al., 2010 (Seillier et al., , 2013 . Not least as regards social behaviour, the pharmacology of cannabinoids is complex (and confusing) but, as reviewed by Gururajan et al. (2010) , tetrahydrocannabinol (the main active constituent of cannabis) and acute exposure to synthetic agonists generally suppress social interaction. Their effects are blunted by the (non-psychotropic) antagonist, cannibidiol, and by drugs interfering with endogenous cannibinioid metabolism (Trezza and Vanderschuren, 2008) . Though the potential influence of cannibinoidergic mechanisms on anxiety should not be neglected, comparisons of the modulation by cannibinoid agonists vs NMDA antagonists of social interaction could offer novel insights into the origins and control of NS (Almeida et al., 2013; Gururajan et al., 2010; Seillier et al., 2010 Seillier et al., , 2013 .
Another agent of interest is the hallucinogen, Lysergic acid diethylamide (LSD), which behaves as a potent agonist at 5-HT2A (and D2) receptors. LSD produces a discriminative stimulus in rats which is potentiated by PCP (Winter et al., 2000) . Chronic exposure of rats to low doses of LSD leads to impaired social interaction, and a broader phenotype reminiscent of the effects of acute and sub-chronic treatment with NMDA receptor antagonists. This includes: elevated release of glutamate in the PFC; hyperlocomotion (blunted by olanzapine and haloperidol); irritability, enhanced aggression, and a reduction in sucrose consumption suggesting an anhedonic state (Marona-Lewicka et al., 2011) . This model warrants further evaluation.
The 3 chamber test in mice has been widely used to explore sociability, social preference, social motivation and social novelty discrimination, albeit mainly in the field of autism (Silverman et al., 2010; Millan and Bales, 2013) . In a recent study, resistance to antipsychotics and sensitivity to D-Cycloserine were used as criteria of "predictive" validity to characterise a model of disruption of social preference by pharmacological stimuli (Hanks et al., 2013) . While these criteria may be debatable (D-Cycloserine has only been used adjunctively in humans and it is not consistently effective against NS) (Section 4.6) (Davis et al., 2014; Javitt, 2012) the findings are interesting. Thus, PCP was inactive, whereas a GABAA inverse agonist diminished sociability and its actions were blunted by D-Cycloserine, but neither by clozapine nor the anxiolytic, alprazolam (Hanks et al., 2013) . In view of interest in GABAAα2 subunit agonists (not unfortunately tested) for treating NS and other symptoms of schizophrenia (Section 4.4), additional research with this model is justified.
Developmental models
Social interaction is the readout that has been most widely exploited in early-life and adolescent neurodevelopmental models for schizophrenia, employing a diverse suite of perturbations from (1) prenatal stress and disruption of neurogenesis to (2) perinatal ventral hippocampus lesions (VHL) and exposure to viral mimics/pro-inflammatory agents to (3) post-weaning isolation (Fatemi and Folsom, 2009; Fone and Porkess, 2008; Meyer and Feldon, 2010; Piontkewitz et al., 2012; Pratt et al., 2012; Tseng et al., 2009) . A highly consistent observation has been reductions in social interaction in adults, as discussed by Wilson and Koenig (2014) and Moser (2014) , in this Special Volume.
One interesting example is VHL in rats, which is usually effected by local injection of isobotenic acid at post-natal day 7. Decreases in social interaction are already seen during adolescence (prior to the appearance of changes related to positive symptoms) and they persist throughout adult life (Tseng et al., 2009) . Early emergence may be related to prodromal NS in humans prior to the first frank psychotic episode (Fusar-Poli et al., 2013a . The decrease in social interaction, which is antipsychotic-insensitive, is accompanied by increased aggression and impaired social memory, observations accentuating the point that changes in a readout for "NS" should never be examined independently of other behaviours when contemplating their relevance (Pratt et al., 2012; Tseng et al., 2009 ). More generally, it is important to confirm, as has been achieved in several studies, that alterations in social interaction can be dissociated from anxiety (Moser, 2014) .
It is intriguing that VHL-induced decreases in social interaction were attenuated by the neurotrophic agent, cerebrolysin, which enhances synaptic plasticity in the PFC and limbic structures (Vázquez-Roque et al., 2012 . Conversely, though few data with antipsychotics are available for developmental models, they do not seem to be effective in reversing social interaction deficits, including those seen in the VHL paradigm (Koike et al., 2009; Lee et al., 2007; Neill et al., 2014; Rueter et al., 2004; Tseng et al., 2009) . By analogy to pharmacological models of NS, this lack of reversal by antipsychotics mirrors the situation in patients, but deficits in social interaction seen in a viral model of perinatal inflammation were, contrariwise, reversed by D-Serine (Nagai et al., 2012) .
As for other behavioural readouts, reductions in social preference in a 3 chamber test were seen in adult mice that had undergone perinatal inflammation (Smith et al., 2007) . In this procedure, decreases in pup play were perhaps related, like the adolescent reductions in social interaction following VHL, to the high-risk prodromal state and justify further exploration (Kirsten et al., 2010) . Indeed, as cogently argued by Trezza et al. (2011a Trezza et al. ( , 2011b , adolescent play in rats (and social proximity in mice) could be profitably exploited to characterise social motivation and reward in developmental and other models of schizophrenia (Section 5.8).
5.5.3. Genetic models: transgenic mice Despite high heritability, the genetics of schizophrenia are heterogeneous, complex and multi-factorial with a polygenic burden of minor risk factors distributed across hundreds of genes in most patients, whereas a minority of subjects reveal (usually de novo) high-impact genetic aberrations involving larger, structural (copy number) variants. Not only protein-coding genes are implicated: for example, there is a strong association between the micro-RNA, miR137 -a regulator of cortical neurodevelopmentand schizophrenia, though any specific role in the genesis of NS awaits elucidation (Millan, 2013 , Sullivan et al., 2012 . Note that many genetic risk factors for schizophrenia overlap with those for other developmental disorders and/or bipolar depression (Andreassen et al., 2014; Malhotra and Sebat, 2012; Purcell et al., 2014; Sullivan et al., 2012) .
These elements complicate the generation of broadlyrelevant genetic models for schizophrenia and, to reiterate the point made above, no genetic model has been described that specifically and exclusively is aimed at reproducing NS. Nonetheless, considerable progress has been made, as expertly discussed by O'Tuathaigh et al., 2014 in this Special Volume. Much experimental work has been influenced by genetic susceptibility factors in patients, with several recent studies focussing on: (1) genes revealed by Genome-Wide (unbiased) Association Studies and (2) rare Copy Number Variants (Hiroi et al., 2013; K.W. Lee et al., 2012) . Interestingly, the genes concerned tend to control developmentally-regulated synaptic networks and signalling plasticity, often with the participation of NMDA receptors. Hence, genetic models for schizophrenia often converge onto mechanisms targeted by pharmacological and developmental models.
Perhaps the best known Copy Number Variant linked to schizophrenia is 22q11.2 where deletions and duplications are also related to autism -including Di George syndrome, which has an about 30 fold greater risk of schizophrenia (Baker and Skuse, 2005; Hiroi et al., 2013; Sebat, 2012, Millan, 2013) . Many genes are involved in this accrued risk of psychosis and the (not always "psychosislike") behavioural changes in mice with manipulation of this region, but of special interest is a 200 kB region containing the Serp5 gene (Hiroi et al., 2013) . Its overexpression facilitates affiliative social behaviour whereas deletion leads to its diminution and -further suggesting a link to NS -delayed acquisition of rewarded approach behaviour (Harper et al., 2012; Suzuki et al., 2009 ). This gene merits additional analysis.
One of the most robust findings to emerge from Genome Wide analyses was the association of several polymorphisms in the developmentally-important Major Histocompatability Complex (MHC) with schizophrenia (Andreassen et al., 2014; K.W. Lee et al., 2012; Sullivan et al., 2012) . Schnurri-2 (MHC-binding protein 2), constitutively binds to and inhibits Nuclear Factor-kappa B which itself acts at the MHC promoter to enhance gene expression. Schnurri-2 knockout mice show widespread brain inflammation and GABAergic interneurone down-regulation linking this model to developmental paradigms. Further, they reveal both anhedonia (decreased sucrose consumption) as well as reduced nestbuilding behaviour, a behavioural change related to NS and observed in, for example, animals with disrupted NMDA receptors and developmental models for schizophrenia (Baharnoori et al., 2012; Halene et al., 2009; Takao et al., 2013) . Attenuation of deficits in Schnurri-2 deficient mice by anti-inflammatory drugs reinforces the notion that inflammation-related disruption of glutamatergic transmission is linked to schizophrenia (Müller et al., 2013) . This is of interest in the light of clinical investigations of the potential utility of cyclo-oxygenase inhibitors and minocycline. The latter agent acts via anti-inflammatory mechanisms (though not exclusively) to exert a surprisingly consistent pattern of efficacy against NS in patients (Davis et al., 2014; Dean et al., 2012; Khodaie-Ardakani et al., 2014; Levkovitz et al., 2010; Liu et al., 2014; Monte et al., 2013; Müller et al., 2013) .
Another gene worth citing is Neuregulin-1 since, amongst other actions, it is inhibitory to Src Kinase-facilitation of NMDA receptor-mediated signalling and may be overexpressed in schizophrenia (Pitcher et al., 2011) . Interestingly, in line with the importance of correct gene dosage (Millan, 2013) , both over and under-expression of the Neuregulin-1 gene in mice disrupts social behaviour, and the effects of its genetic manipulation depend on the nature of the mutation, underscoring the complexity of even single gene models for studying NS (O'Tuathaigh et al., 2007 (O'Tuathaigh et al., , 2014 .
As for glutamatergic transmission itself, there are fewer data than might be imagined. Nonetheless, genetic disruption of D-Amino-Acid Oxidase (which catabolises D-Serine) partially restores deficits in social behaviour provoked by mutations in the NMDA receptor subunit, "Grin1", a point worth underlining in light of positive data with D-Amino-Acid Oxidase inhibitors against NS in patients (Labrie et al., 2010; Lane et al., 2013) . Along these lines, the gene encoding the ionotropic GluD1 glutamate receptor is linked both to schizophrenia and to anomalous operation of frontothalamic networks (Nenadic et al., 2012) . Its deletion is associated with a reduction in social interaction abrogated by D-Cycloserine (Yadav et al., 2012) . Finally, the GABAB receptor agonist, baclofen, opposed the reduced sociability triggered by genetic deletion of the NR1 subunit of NMDA receptors, likely by restoring NMDA-GABAergic and excitatory-inhibitory balance in the cortex -the clinical influence of GABAB agonists on NS remains, surprisingly, unknown despite their current development for management of autism (Gandal et al., 2012; Millan, 2013) .
Though surprisingly little information pertinent to social behaviour has emerged from genetic manipulation of dopaminergic transmission, mice with a null mutation for the DA transporter showed a deficit in the social transmission of food preference. This alteration is clearly relevant to impaired social cognition but is also of interest with regard to NS since, like other deficits, it was blunted by pregnenelone, a positive modulator of transmission at NMDA and GABAA receptors under study for alleviation of NS in patients (Sections 4.4 and 4.5) (Wong et al., 2012) . As regards DA receptors themselves, studies have to date focussed more on their relationship to avolition than to social behaviour (Section 5.6.4). Nonetheless, inasmuch as D3 receptor over-expression decreases motivation, and D3 receptor inactivation is associated with enhanced social novelty discrimination, social interaction and nest-building behaviour in mice, further study of the significance of D3 and other classes of DA receptor to asociality appears warranted (Gross et al., 2013; Watson et al., 2012) .
Finally, oxytocin has not unnaturally evoked considerable interest, and genetic interference with oxytocin receptors consitently disrupts social behaviour, cognition and communication in mice with both homozygotes and -perhaps more specifically -heterozygotes displaying deficits in both sociability and social novelty preference (Goodson and Thompson, 2010: Millan and Bales, 2012; Pobbe et al., 2012; Sala et al., 2013) . Importantly, these models exemplify the difficulty of extrapolating to any specific diagnostic entity in humans since observations have mainly been linked to autism rather than schizophrenia, despite evidence that the latter disorder is characterised by defective oxytocinergic transmission (Section 4.8) (Meyer-Lindenberg et al., 2011) . 5.5.4. Genetic models: specific mice strains In addition to transgenic strategies, it is interesting to consider the complementary "genetic" strategy of comparing specific mouse strains.
For example, "reeler" mice are deficient for the risk gene reelin which is epigenetically silenced in GABAergic interneurons both in the PFC of subjects with schizophrenia, and in corresponding animal models (Millan, 2013; Pratt et al., 2012) . Reelin mice display reduced levels of oxytocin (Liu et al., 2005; Millan, 2013) and, while NS like symptoms have not yet been described, social withdrawal has been seen in another instructive strain, "sandy" mice, deficient in the schizophrenia risk gene, dysbindin (Talbot, 2009) .
As a further example, the "Black and Tan Brachyury" (BTBR) inbred line has attracted particular attention. This mouse displays a spectrum of deficits in social behaviour, sociability and social communication, including scent marking and Ultrasonic Vocalisations (USV), which collectively underscore its pertinence to autism, as well as schizophrenia (Meyza et al., 2013; Scattoni et al., 2013; Yang et al., 2013) . Indeed, BTBR mice reveal decreases in grey matter volume in the PFC and anomalies of white matter, recalling observations in schizophrenic patients (Section 3.2) (Dodero et al., 2013; Ellegood et al., 2013) . The recent finding that levels of kynenurenic acid are elevated in BTBR mice is especially interesting (McTighe et al., 2013) since, as mentioned above, this endogenous antagonist of NMDA receptors has been implicated in the pathophysiology of schizophrenia (Millan, 2005; Müller et al., 2013) . Moreover, the Glycine B/NMDA receptor partial agonist, D-cycloserine, improved sociality in this strain (Burket et al., 2013) . Finally, in light of the implication of frontocortical mTOR (mammalian target of rapamycin) over-activation in the impairment of social cognition in schizophrenia (Meffre et al., 2012) , it is interesting that the inhibitor, rapamycin, promoted sociability in BTBR mice (Burket et al., 2014) It is not always evident to find the right strain for comparative studies, but more intensive characterisation of BTBR and other inbred mice populations should provide further insights into the origins and modulation of NS O'Tuathaigh et al., 2014). 5.6. Amotivation, avolition and disruption of anticipatory reward 5.6.1. Procedures for evaluating mechanisms controlling reward, motivation and hedonic states Generally speaking, deficits in motivation have been less extensively studied than disruption of social behaviour in rodent models for schizophrenia. Nonetheless, data are beginning to accumulate with clear indications of how progress can be made, and comparisons can instructively be entertained to a larger opus of data showing that dopaminergic pathways fulfil a crucial role in motivation and reward processes: see articles by Neill et al., 2014 , Moser, 2014 and O'Tuathaigh et al., 2014 in this Special Volume and, in particular, that of Barnes et al., 2014 who authoritively discuss the surprisingly broad range of procedures available to characterise reward-related deficits in rodent studies of NS.
Many studies have concentrated on sucrose consumption and, in certain cases, intracranial self-stimulation as direct measures of hedonic states. However, as discussed above (Section 2.1), schizophrenic patients primarily display impairments of motivation (anticipation, wanting) rather than reward (experience, liking) ( Table 1) (Foussias et al., 2014; Huxley and Fonseca, 2014) , which are differentially integrated by corticlimbic circuits (Berridge et al., 2009; Berridge and Kringelbach, 2013; Strauss et al., 2014) . Hence, experimental procedures that differentiate these functions are especially significant (Barnes et al., 2014; Pratt et al., 2012) . In the context of motivation for reward, procedures reflecting the effort (physical and/or cognitive) that a subject is prepared to invest to obtain a reward are crucial: these include Progressive/Random Reinforcement procedures where, for each successive reward, the work (level presses needed) increases/varies (Bardgett et al., 2009; Barnes et al., 2014; Ghods-Sharifi and Floresco, 2010; Hosking et al., 2014; Salamone et al., 2012; Ward et al., 2011) . Finally, apart from cost, the element of delayed gratification, whereby a preference for a more substantial yet later reward over a smaller yet more rapidly available reward ("delayed discounting") is likewise accessible to experimental study (Barnes et al., 2014; Pittaras et al., 2014) . This is relevant to schizophrenics in which a prospective (uncertain) reward may be undervalued, hence diminishing motivation to invest in its acquisition (Gold et al., 2013; Salamone et al., 2012; Strauss et al., 2014) .
Pharmacological models
As analysed by Neill et al., 2014 , it has been suggested that the suppression of sucrose preference in rats by acute administration of (usually high) doses of ketamine and other NMDA receptor open channel blockers may be pertinent to the NS of schizophrenia. For example, Baird et al. (2008) demonstrated a reduction in the intake of palatable solution of sucrose without any specific interference with taste, while Vardigan et al. (2010) reported that dizocilpine reduced sucrose preference in a manner separable from any interference with motor function: its actions were blunted by D-Serine and clozapine, but not by haloperidol. Inasmuch as NMDA antagonists manifest (rapid-onset) antidepressant properties, it seems unlikely that a depressogenic action is involved: indeed, deficits in sucrose preference associated with models of depression are alleviated by comparatively low doses of ketamine, a drug in development for resistant depression .
Other studies suggest that chronic exposure to NMDA antagonists leads to a post-withdrawal phase of anhedonia in tests of sucrose consumption and intracranial self-stimulation, possibly due to depletion of corticolimbic pools of DA (Barnes et al., 2014; Jentsch et al., 1997; Millan et al., 1999; Millan, 2006) . These observations merit further consideration but they appear to principally effect a change in consummatory as opposed to anticipatory anhedonia so their genuine relevance to NS remains uncertain. Indeed, Neill et al., 2014 mention that chronic PCP does not interfere with anticipatory reward as measured in a Progressive Ratio model of motivation. On the other hand, using a chronic intermittent protocol of PCP administration and a T-maze with a choice between a high effort/high reward vs low effort/low reward arm, rats opted for the latter suggesting low motivation for investing effort to attain the greater reward (Morris et al., 2005; Pratt et al., 2012) . Furthermore, as discussed by Barnes et al., 2014 , amphetamine-withdrawn rats show a reduction in behaviour directed towards the performance of sexual behaviour, rather than any deficits in the act itself. The anhedonic-like state that accompanies cocaine-withdrawal has been related to activation of mesolimbic populations of kappa opioid receptors: their blockade is associated with antidepressant properties, but whether this mechanism exerts a direct impact on NS remains to be elucidated (Chartoff et al., 2012) .
Finally, many elegant mechanistic studies have been undertaken to examine neuronal circuitry implicated in reward processes and potentially disrupted in NS: for example, GABAergic inactivation of the PFC leads to altered dopaminergic encoding of expected rewards (Jo et al., 2013) . However, such specialised procedures cannot realistically be used for characterisation of potential pharmacotherapy on a broad scale.
Thus, currently there is no simple and well-established pharmacological model for studying NS related to amotivation, but some promising avenues of research justify further exploration. In future work, elements of anticipation and effort invested to attain reward warrant more intensive study (Section 5.8).
Developmental models
Great care must be taken to ensure that a behavioural change genuinely relates to a schizophrenia-like phenotype and specifically to NS. An interesting example was provided above as regards the altered social interaction seen in neonatal VHL rats, and this model serves to illustrate the comparable complexity of studies of reward mechanisms (Brady et al., 2008; Tseng et al., 2009 ). Le Pen et al., 2002 showed that VHL subjects display a diminished preference both for a saccharine solution and for a conditioned place preference to amphetamine, indicative of an impaired hedonic state (Trezza et al., 2011a (Trezza et al., , 2011b . However, it is unclear how this anhedonia relates to the reward deficits of NS in schizophrenia since this model did not incorporate measures of anticipatory motivation. Conversely, this dimension was addressed by Brady et al. (2008) using a Progressive Ratio schedule to determine the effort and motivation that VHL rats were prepared to invest for attaining their goal (an injection of methamphetamine), a model with greater face value for NS. Ironically then, VHL rats actually worked harder before responding was discontinued. This observation was interpreted as reflecting an increase in the rewarding properties of methamphetamine -commensurate with the comorbidity of addictive behaviour in schizophrenics (Heidbreder and Newman, 2010) . Nevertheless, it might alternatively be considered as challenging the relevance of decreased sucrose consumption/amphetamine placepreference in rodents to the NS of schizophrenia. Further work is necessary to clarify this issue. Oddly enough, there are little other data concerning NS-related changes in motivation with developmental models of schizophrenia, a field ripe for expansion using procedures mentioned above and more comprehensively discussed in Barnes et al. (2014) .
Genetic models
The preceding section evoked the important elements of anticipation and motivation to work for reward, of which a deficiency epitomises NS (see also Section 3.3). This provides a useful transition to several elegant and interrelated studies of amotivation undertaken in rats with geneticallymanipulated D2 and, more recently, D3 receptors (Drew et al., 2007; Li et al., 2011; Simpson et al., 2011 Simpson et al., , 2014 Trifilieff et al., 2013; Ward et al., 2009 Ward et al., , 2011 .
Transgenic mice that selectively overexpress D2 receptors on medium spiny neurones in the striatum may be compared to the "overactivation" of subcortical dopaminergic transmission seen in schizophrenia. These animals stop responding sooner in Progressive and Random Ratio schedules of lever-pressing for food. This cannot be explained by satiety, fatigue or lack of hedonic pleasure, rather to a lack of willingness to work and to insensitivity to the value of future reward, perhaps due to poor internal representation or faulty computation of cost vs benefit relationships (Drew et al., 2007; Ward et al., 2012) . This dissociation between incentive motivation and hedonic appreciation of reward resembles the profile of NS in schizophrenia underscoring the interest of the model (Table 1) (Kring and Barch, 2014; Strauss et al., 2014) . The effects of striatal D2 receptor overexpression likely involve a frontocortico-striatal loop and disruption of excitatory-inhibitory signalling in the PFC (Li et al., 2011) , supporting relevance to the induction and expression of NS (Section 3).
As regards potential modulation, 5-HT2C receptors were up-regulated in the striatum of D2 receptor overexpressing mice, and 5-HT2C receptor antagonists rescued the decreased motivation . Accordingly, it was posited that 5-HT2C receptor antagonists may be useful for restoring motivation in schizophrenia. However, despite concomitant benefits for moderating social anxiety and depression, there is a risk of exacerbating positive symptoms since 5-HT2C receptors inhibit mesolimbic release of DA Meltzer, 2012; Millan, 2006) . Indeed, this was the basis for proposing 5-HT2C agonists for the treatment of schizophrenia and, very recently, the first clinical data were released with tentative improvement of both positive symptoms and, surprisingly, NS (Shen et al., 2014) . Thus, the status of 5-HT2C receptors as a target for the control of NS and other dimensions of schizophrenia awaits further clarification (Section 4.3).
More recently, another model was introduced in which a lentivirus elicited (more pronounced) D2 receptor overexpression specifically in the nucleus accumbens and, in contrast to the above model, motivation to work to obtain a reward was enhanced, with no change in consummatory behaviour. This observation mirrors the increased motivation produced by enhanced mesolimbic release of DA in humans and animals, and provides a counterpart to its diminution by DA antagonists (Salamone et al., 2012; Barnes et al., 2014; Trifilieff et al., 2013) . The data are also globally consistent with the use of psychostimulants to alleviate NS . However, the data also emphasise that: (1) at first site similar models can show important differences; (2) the role of DA in reward mechanisms is complex and regionally-specific and (3) direct exploitation of dopaminergic substrates for the control of NS might need to be local. This presents a formidable if not insuperable therapeutic challenge -further underlined by the central importance of D2 receptor blockade in the control of positive symptoms.
A final and rather more auspicious, dimension of complexity is provided by the contrasting roles of D3 receptors -which are not differentiated from D2 receptors by any antipsychotic currently available for prescription . D3 receptor overexpression restricted to the striatum led to decreased motivation in a Progressive Ratio schedule of reinforcement (Simpson et al., 2014) . This observation is important since it suggests that blockade of striatal D3 receptors may counter the amotivation of schizophrenia. Several other observations suggest that D3 receptor blockade should counter NS, such as facilitation of nesting behaviour and social contact (Gross et al., 2013) . Moreover these actions are complemented by a PFC-mediated and broad-based enhancement of social cognition and multiple neurocognitive domains (Table 2 ) (Gross et al., 2013; Millan et al., 2007; Millan and Brocco, 2008; Nakajima et al., 2013; Watson et al., 2012) . D3 receptor blockade also counters co-morbid drug-seeking behaviour, though hypothesised benefits for the control of positive symptoms await clinical evaluation (Gross et al., 2013; Heidbreder and Newman, 2010; Millan and Brocco, 2008; Mugnaini et al., 2013) . Bizarrely enough, despite the availability of well-tolerated and thoroughly-characterised D3 receptor antagonists, their influence on NS has never been specifically determined at appropriate doses (op. cit.).
Despite this intriguing and extensive body of data concerning dopaminergic mechanisms, disappointingly few data are available concerning NS-related impairment of motivation from other genetic models for schizophrenia (O'Tuathaigh et al., 2014) .
Blunted expression: procedures and readouts of potential utility
In a sense, rodents "speak to us with their feet", so their (loco)motor behaviour is an expression of their emotional and internal state (Figure 6 ). Hence, behaviours like decreased sociability and social interaction, reduced lever pressing for reward and decreased anticipatory approach behaviour may at least partially reflect blunted expression (Barnes et al., 2014; Wilson and Koenig, 2014) . However, this possibility does not appear to have been formally addressed, nor this sub-dimension of NS factored out in studies evoked above. Furthermore, there appears to be no currently-accepted and broadly-used readout specifically related to blunted expression for use in animal models. The following points are nevertheless of interest.
There are indications that ketamine induces emotional blunting in humans (Abel et al., 2003; Millan, 2005) and its disruption of amygdala-integrated fear conditioning in rats, as measured by both behavioural and neurochemical measures, was proposed as a measure of emotional blunting irresponsive to conventional antipsychotics (Pietersen et al., 2007) . However, it is hard to be certain that this model relates to NS rather than modulation of anxiety per se and further validation is awaited before its utility can be more rigorously assessed.
Likewise, though increased immobility in a forced swimming test following chronic exposure of NMDA antagonists has been considered analogous to the induction of "emotional blunting" in schizophrenia, the specificity and pertinence of this readout remains debatable (Neill et al., 2014) . Though the induction of immobility by neuroleptics/D2 receptor blockade might be claimed as related to "secondary NS", it is hard to differentiate a putative impact of drugs on motor behaviour, depressed mood and other factors from any putative induction of "emotional blunting". Nonetheless, the enhanced immobility associated with chronic exposure to PCP was reversed by D-Cycloserine (and sub-chronic clozapine, but not haloperidol) suggesting that further study is warranted (Murai et al., 2007; Turgeon et al., 2007) .
The procedures outlined above, despite their interest, still require more rigorous characterisation, so several other approaches of potentially greater face validity for examining blunted expression are evoked below (Section 5.8.2).
5.8.
Prospects for further refinement of experimental studies of NS 5.8.1. Major lines of study to date and possible extensions: motivation and social interaction From the above discussion, it is apparent that a surprisingly broad range of readouts and measures are potentially available for examining social behaviour, reward and motivation in rodent models for schizophrenia ( Figure 6) (Lai et al., 2014; Lahvis et al., 2011; Markou et al., 2013; Silverman et al., 2010; Trezza et al., 2011a Trezza et al., , 2011b Tzschentke, 2007) . On the other hand, the number of pharmacological mechanisms suggested to actually modify NS-like behaviours in animal models (Table 2) , and the breadth of measures exploited to date is fairly restricted.
For example, little has been done as regards amotivation in developmental and genetic models. Measures of sucrose consumption as a readout of hedonic states (consummatory reward) have been (questionably) prioritised and, even in pharmacological models, the rich repertoire of procedures for differentiating changes in anticipatory vs consummatory anhedonia has been under-utilised. Though the specialist nature of some behavioural paradigms may admittedly be dissuasive for neophytes, there is clearly much that could be undertaken (Barnes et al., 2014; Pittaras et al., 2014) .
As regards social behaviour, social interaction has greatly predominated as a readout (not invariably with rigorous controls for interference by factors like social anxiety and social cognition), and tests of sociability and social novelty preference etc. in mice have been comparatively little adopted (Silverman et al., 2010; Trezza et al., 2011a Trezza et al., , 2011b . Social motivation is a particularly interesting area for improved future study. Trezza et al. (2011a Trezza et al. ( , 2011b pointed out that maternal pup care, sexual behaviour and play are all highly motivating in post-partum females, adults and adolescents/juveniles, respectively. The latter two behaviours could be instructively employed in experimental studies of NS in rats, employing either operant, maze-based and or place-conditioning paradigms -for adolescent mice, social proximity would be the readout. For example, in a conditioned social place preference procedure, rats preferred a compartment previously associated with a social partner compared to one where it was absent (Tzschentke, 2007) . This preference is disrupted by sub-chronic PCP, and further exploration of this procedure would be of considerable interest (Schwabe et al., 2006; Thiel et al., 2008) . Learning in T-maze models is also of interest in light of the need to remember and recall past rewarding experiences in order to anticipate, positively value and strive for potential future rewards (Berridge et al., 2009; Berridge and Kringelbach, 2013; Kring and Barch, 2014; Trezza et al., 2011a Trezza et al., , 2011b .
There are ample opportunities for substantially enriching studies of social motivation and reward in animal models for schizophrenia focussing on NS.
Alternative approaches to evaluating diminished emotional expression
As pointed out in Section 5.7. there is considerable room for improvement as regards the NS sub-dimension of decreased expression.
One human trait poorly back-translatable into animals is fully syntactical, recursive and abstract language (Fitch et al., 2010; Poeppel, 2012) , of which a loss of fluent production (alogia) characterises NS (Table 1) (Foussias et al., 2014) . While the full complexity of verbal language -and non-verbal visual signals -cannot be studied in rodents, there are other modes of social communication that could prove instructive, such as the olfactory and tactile: mutual grooming in rodents -and primates -is promoted by oxytocin and relevant both to restricted expression and to asociality (Dunbar, 2010) . The most dynamic, pro-active and rich mode of exchange is arguably USVs. USVs are emitted in a context and emotional statedependent manner, notably during tests of social preference and social interaction amongst adults and/or pups, and in a manner influenced by genetic background. Thus, the monitoring of USVs (quantity, spectral distribution, pattern) and their modulation during tests of social contact could provide major insights relevant to decreased expression -as well as social motivation and engagement -though extrapolation of findings to human speech (alogia) should be made with great caution, if at all (Lahvis et al., 2011; Nikiforuk et al., 2013; Woḧr and Schwarting, 2013; Yang et al., 2013) . Underpinning the interest of such work, altered emission of USV accompanies reduced social interaction, disruption of nest-building behaviour and compromised subcortical dopaminergic transmission in models of pre-natal infection/ inflammation (Baharnoori et al., 2012; Kirsten et al., 2010 Kirsten et al., , 2012 . Tactile and USV means of communication -as well as yawning -have been advocated for studies of social cognition and could well prove useful in work on NS in rodents (Millan and Bales, 2013) .
Facial expressions and licking patterns have been monitored during consumption of rewarding and aversive solutions, so it would be worth assessing a putative role in the active transmission of affective state to conspecifics (Berridge et al., 2009; Lydall et al., 2010; Peciña and Smith, 2010) .
Combinations of developmental and genetic models in rodents
In much the same way that studies of individual risk genes in humans are migrating to analysis of epistatic interactions between genes (Purcell et al., 2014; Sullivan et al., 2012) , there is a move to combine risk factors as a more realistic approach for generating core feature of schizophrenia in rodents (O'Tuathaigh et al., 2014; Hida et al., 2013) . While double genetic manipulations are feasible, of greater interest are studies were the interface between genetic and environmental risk factors has been mimicked by superimposing a developmental insult upon a vulnerable genetic background. In one particularly interesting example, Desbonnet et al., 2012 showed that social defeat in adolescent mice synergistically impaired social interaction when performed in subjects bearing a deletion of the gene encoding Neuregulin-1. Further, other studies have exploited mice with mutated genes for the risk gene, Disrupted in Schizophrenia-1, and combined this genetic background with perinatal inflammation. This dual-hit paradigm is especially interesting since inflammatory mechanisms converge on many intracellular signals that interact with this protein (Abazyan et al., 2010; Kamiya et al., 2012) . It was accompanied by reductions in social preference and social interaction, observations unaffected by antipsychotics (Nagai et al., 2011) . Models combining risk factors seem a particularly fruitful direction for additional study since they are more faithful to multi-hit concepts of the origins of schizophrenia (Figure 1) . 5.8.4. Induction of pathophysiological mechanisms in discrete brain regions A likewise novel yet rather different approach, mirroring VHL in rats (Tseng et al., 2009 ) and inactivation of GABAergic transmission in the PFC (Jo et al., 2013) , consists in the induction of pathophysiological mechanisms in discrete brain regions to more precisely define the neural substrates underlying NS. For example, localised expression of a dominant-negative Disrupted in Schizophrenia-1 mutant gene in mouse PFC provoked oxidative stress and behavioural changes reminiscent of NS, including aberrant social behaviour and reduced performance in a operant procedure of effort-related reward procurement (Johnson et al., 2013) . Further, not just genetic manipulations are concerned. For example, rather than induction of systemic inflammation, intra-hippocampal injection in neonatal rats of the pro-inflammatory agent, lipopolysaccharide, led to microglial activation and deficits in adult social behaviour (Zhu et al., 2014) . 5.8.5. Alternative species: from primates to zebrafish models Certain parameters relevant to social motivation and communication, and interlinked both with NS and social cognition, cannot realistically be modelled in rodents, most obviously those pertaining to the visual domain. This raises the possibility of studies in non-human primates. For example, analysis of gaze-following has been forwarded as a strategy for improving our understanding of social cognition, and opportunities likewise may arise in primates for gaining insights (behaviour, imaging, EEG etc.) into the asociality of NS and its modulation (Millan and Bales, 2013) . In addition, primates have been employed for analysing the role of PFC sub-territories and the amygdala in social motivation and reward-guided behaviour, processes disrupted in schizophrenia (Murray and Rudebeck, 2013) (Section 3.3). Social interaction (cognition) is well-studied in primates (Byrne and Bates, 2010) , and the interplay between dopaminergic transmission and social hierarchies has been explored in relation to cocaine reward, providing another experimental template of potential relevance to NS (Nader et al., 2012) . A further possibility may be studies of the social effects of ketamine, which has been exploited as a pharmacological mimic for schizophrenia in studies of cognitive performance and ERPs in primates (Gil-da-Costa et al., 2013; Nakako et al., 2013) . As recently reviewed elsewhere (Millan and Bales, 2013) , and mirroring models in rodents, developmental procedures in primates involving induction of inflammation, disruption of neurogenesis and early-life cerebral lesions could be expanded for the investigation of NS. Such studies must only be undertaken in specialised labs, with rigorous ethical precautions, and preferably with freely-moving subjects in a naturalistic and highly social environment, and they should best be kept to a minimum. Nonetheless, they could prove crucial for validation of novel therapeutic concepts, and in a translational context before advancing a promising agent into humans for potential relief of NS.
In a mirror image of the primate, there is increasing interest in zebrafish for the rapid screening of potentially-novel psychotropic drugs, and for enhancing our understanding of the cellular origins of neurodevelopment disorders like schizophrenia (Maaswinkel et al., 2013; Norton, 2013) . Genetic homology is substantial with mammals and gene-manipulations are rapid and straightforward; glutamatergic and dopaminergic mechanisms are well characterised; reward and social behaviour can be monitored; and administration of ketamine is known to disrupt social interaction and the dynamics of social groups, with its actions blunted by sulpride -but not haloperidol (Collier and Echevarria, 2013; Seibt et al., 2011; Zakhary et al., 2011) . Once novel mechanisms for potentially modulating NS have been identified in higher species, zebrafish may prove a useful initial model for screening the corresponding drugs.
5.8.6. More intensive linking of behavioural observations to mechanistic bases Apart from the above-mentioned importance of enriching behavioural readouts, it would also be advantageous to more closely link behavioural indices of NS to their potential neural and neurochemical substrates using structural and functional imaging, electrophysiological parameters, and dialysis measures of the release of glutamate, DA and oxytocin etc.: such work is being intensified (Murai et al., 2007; Neill et al., 2010; Piontkewitz et al., 2012; Pratt et al., 2012) . While the focus here (and elsewhere) has very much been on glutamategic and dopaminergic mechanisms, together with oxytocin where the interface with social cognition is concerned, there should be greater attention to other relevant cellular mechanisms modulating reward and social behaviour, and potentially related to core features of NS. For example, cannabinoids may transduce the impact of PCP on social behaviour in rodent models and they interact with corticolimbic dopaminergic transmission and control reward mechanisms. Further, cannabidiol (which enhances endogenous levels of anandamide) reduced NS and other symptoms in a small trial in schizophrenic patients, while an increase in the nucleus accumbens density of CB1 receptors has been correlated with the intensity of NS in patients (Section 3.6) (Ceccarini et al., 2013; Leweke et al., 2012; Seillier et al., 2010 Seillier et al., , 2013 .
It is likely that we have still only identified a small minority of endogenous mechanisms potentially exploitable by pharmacotherapy for the improvement of NS in schizophrenia (Table 2) .
5.8.7. Evaluating novel mechanisms for potentially preventing NS Drug treatments have almost invariably been undertaken in adults upon acute administration, and after the appearance of changes reflecting psychosis. It should be evaluated whether longer-term administration of agents to adolescent subjects prior to the appearance of positive-like symptoms in adults may: (1) alter those components of NS already present and (2) hinder their emergence and progression in adults. This would be analogous to the study in models for schizophrenia of potential strategies for preventing the onset of structural changes and cognitive impairment (Clifton et al., 2013; Piontkewitz et al., 2012) . Indeed, more generally, there is a need to intensify studies of animal models during (and just after) the adolescent phase when NS-like changes may be apparent or emerging, even prior to the manifestation of changes related to positive symptoms.
Finally, while it might be assumed that only pharmacotherapeutic approaches can be evaluated for their potential efficacy against NS -or for impeding the development of NS -recent work suggests that experimental models may also be amenable to the study of "cognitive-behaviouralpsychosocial" strategies for preventing the emergence of NS (H. ).
Concluding comments
As summarised in Table 3 , and more comprehensively articulated in the individual articles of this Special Volume, the current lack of effective treatment for the debilitating NS accompanying schizophrenia has triggered considerable efforts to: refine their clinical characterisation and measurement; deepen our understanding of the neural and neurochemical substrates of NS; improve the performance of clinical trials for innovative and potentially superior therapy; explore clinical strategies for controlling NS complementary to pharmacotherapy; and to broaden and advance animal models and readouts for the experimental study of NS. This all remains very much a "work in progress", many fundamental questions await elucidation, The numbers refer to the papers of this Special Volume dedicated to the issues specified. ) and (10) Neill et al. (in press ). The present paper, in addition to a synthetic overview of all the themes specified above, discusses the neural and neurochemical substrates of NS, a topic not covered in detail in the other papers, and the same holds for cognitive-behavioural-psychosocial therapies for controlling NS.
and the kinetics and complexities of rigorous clinical characterisation of novel medication for NS are likely to remain largely incompressible (Table 3) . Nonetheless, precompetitive, industrial-academic-governmental initiatives like "MATRICS" (US) and the Innovative Medicines Initiative (EU) are proving increasingly beneficial for target characterisation and the development of clinical biomarkers, while an on-going dialogue with the Federal Drug and European Medicines Agencies is likewise useful in the design of clinical trials for the improved control of NS. Overall, there are grounds for cautious optimism. Our knowledge of the causes, characteristics and potential control of NS -and other facets -of schizophrenia is systematically progressing. While much remains to be learned, this affords some hope that we should eventually be in a position to propose novel strategies for the more effective treatment of NS and other symptoms of this devastating disorder.
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